Peptides

More About Khavinson’s Peptides

Natural & Synthesized Khavinson Peptides

Aging and protein synthesis

Aging is a major risk factor for disease and death but what is the cause of aging? Despite many theories it is still unknown. What we know is that as we age our body produces fewer proteins that have a large number of important functions in our body. For example:

  • Proteins are vital to cell division, which is necessary for growth, reproduction and healing.
  • Many proteins keep everything working right by regulating chemical reactions. Examples include enzymes, hormones, blood clotting substances, even receptors in the eyes.
  • Protein is essential for the immune system to defend against foreign invaders such as bacteria and viruses.
  • Proteins help to transport other nutrients around the body by binding to them and then releasing them when and where they are needed.
  • Protein helps to regulate and maintain a proper fluid balance. This helps to maintain proper blood pressure and even lubricate eyes.
  • Certain proteins serve a major structural role in tissues such as muscle and skin and even provide the matrix for bones and teeth.

Basically, our bodies make thousands of specific proteins that serve important roles in everyday functioning — in fact, the human body is about 45% protein on a dry matter basis.

As aging is associated with a decline in the synthesis of protein, it is logical to assume that if the synthesis is restored aging can be slowed down. As it turns out this assumption is correct. Scientists V. Khavinson and V. Morozov have found a way to repair protein production and have achieved incredible results. Using the following methods can increase lifespan by 20-40%.

Triggering molecules

The information about different proteins is stored in the DNA. In order to launch protein synthesis a DNA fragment, a gene, has to be activated by triggering molecules, peptides. Peptides are relatively short chains of amino acids and they are an essential part of the cell self-regulating mechanism:
Cells constantly degrade aged proteins by breaking them down into amino acids and peptides. Some of these peptides match specific parts in the cell DNA following the lock-key principle. As a result, the peptide resumes the synthesis of the protein from which it was originally built. When the protein ages, it is fragmented into the same peptides once again. All of this forms a circular process that is vital to cell life.

However, due to extended exposure to environmental hazards and stress this cell self-regulating mechanism is compromised and we become peptide deficient. Peptide deficiency leads to cell malfunction and eventually to diseases and premature aging. Luckily, we can restore the peptide-protein cycle with peptide supplements.

History

The first peptide product was created for the military in the Russian Military Medical Academy 40 years ago in 1974 by V. Khavinson and V. Morozov since 1977 and it has been authorized for clinical use under the name Thymalin. It cointains thymus peptides, extracted from young calves, that restore the impaired immune system and minimize the risk of cancer by several times. Shortly, Epithalamin, a product formulated with the pineal gland peptides was developed. It prevents premature aging, improves the function of the endocrine, immune, cardiovascular and reproductive systems, lengthens telomeres, restores carbohydrate metabolism, and strengthens bones and joints. It was proven that if administrated together the pineal gland and the thymus peptides can prolong human life substantially. Their high efficiency has been shown in more than 50 experiments on animals and multiple clinical trials in the last 40 years.

Eventually, peptides have been extracted from almost every body system and demonstrated stunning tissue-specific properties, i.e., they have beneficial effects on the organs which they were extracted from.

In the last 40 years these medicines have been taken by more than 15 millions of people and no side effects have been found. The fact is that peptides are apparently evolutionary the oldest cell self-regulating mechanism and as their structure is quite simple they have not undergone any constructional changes over time. That means that peptides in animals and humans are identical. Besides it was also proven that peptide intake can only normalize the protein synthesis and cannot overstimulate it as a cell cannot take more peptides than it needs.

Peptide supplements

For many years the peptide preparations were available only as medicines, in the form of injections. However some years ago Prof. Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology created dietary supplements that can also reduce peptide deficiency and restore peptide-protein cycle in cells. They can be divided into natural and synthesized peptides.

Natural peptides (Cytomaxes)

Natural peptides is a group of peptides of less than 50 amino acids and with a molecular mass of less than 5 kDa, free from foreign DNA or protein substance, extracted from organs and tissues of young calves by a patented method of thorough filtering. 5 kDa is very little. The molecular mass of DNA fragments and proteinaceous infectious particles, the prions, are several times bigger than that. Therefore these peptide supplements are extremely clean products. They do not have any immunogenic or mutagenic properties.
Inside the gastrointestinal tract the natural peptides break down into amino acids and di-, tri- and tetrapeptides that match the DNA in a complementary way and activate protein synthesis in the respective body system. Their performance is gentle and gradual. Their effect continues to grow even after finishing the supplementation course and lasts up to 4-6 months until the peptide-protein cycle is impaired again.

Synthesized peptides (Cytogens)

The analysis of natural peptides was used to detect the most active peptide from a group, which was later replicated in a lab. Synthesized peptide supplement contains only one peptide molecule whereas natural one includes a group of molecules. Synthesized peptides have an immediate impact compared to natural peptides and have a faster, yet more short-lived effect (1.5-2 months). Such peptides are typically used to start the initial peptide deficiency. However, it is advised to switch to natural peptides as a follow-up course.

Both types of peptides are efficient, safe to use, have no side effects and are compatible among themselves and with other products. As for the choice between natural and synthesized peptides, it depends on a particular situation. However, in most cases synthesized peptides, if available, are administered prior to the use of natural peptides.

When and how to take peptides?

It is advised to start taking peptide supplements upon reaching 35 years of age as a preventive measure against premature aging. At this stage two to three 10-day courses of the basic products per year are sufficient to maintain the body’s well-being. These basic products are Vladonix, Cerluten, Ventfort, Sigumir, Svetinorm and if a person works night shifts or often takes intercontinental flights, Endoluten. They regulate the function of the systems that age faster. If required, other peptides could be added as another ten-day course, based on individual needs.

Starting from 40-45 years, two courses a year become necessary, with 2 capsules daily for 30 days per course. The health in the decades to follow will majorly be influenced by the degree of recovery achieved during this period. It is crucial to start timely biannual intake of extensive anti-age courses that include Endoluten, Vladonix, Cerluten, Ventfort, Sigumir, Svetinorm, Chelohart and for men Libidon, Testoluten, for women Zhenoluten and Thyreogen. Additional products are chosen based on individual needs and predispositions. Generally, the older we get, the more organs that require additional support.

Starting from 50-55 years, it is generally recommended to increase the number of courses a year from two to three. If you need to take more than 5 peptide products it is usually advised to split the course in several months so that each month you take 5 products or fewer. Please note for better absorption peptides are taken 30 minutes before meals.

Introduction To Synthetic Peptides

The Saint Petersburg Institute of Bioregulation and Gerontology (SPIBG) of the North-Western Branch of the Russian Academy of Medical Sciences for years has been developing a special approach to a new class of peptide-based supplements. As a result of the analysis of the amino-acidic sequence of peptides extracted from organs and tissues, physiologically active short peptides have been developed and later defined as a class of cytogenes, also known as the synthesized short peptides. This class of dietary supplements is characterized by a faster action compared to extracts: the physiological effects become evident after 24 hours, the main processes related to regulating work and functionality of organs and systems are launched. It is therefore considered highly important to take these synthetic peptides in the earliest stage of biotherapy.

On the other hand, the extracted peptides, widely known as the cytomax class, or the natural peptides, perform in a more delicate and gradual manner due to their so called specific physiological environment: it includes amino acids and microelements typical for that type of tissue from which they have been extracted in terms of quantity and quality. As a consequence of discrepancy in performance and effects of the different classes of peptides (synthesized or natural), SPIBG recommends their step-wise use as more reasonable. For instance, in the first four weeks a course of synthetic peptides can be taken, followed by one to two months of biotherapy based on natural peptides.

Conclusion

There is still no way to stop aging but thanks to the scientists’ intensive work during the last 40 years, we finally have dietary supplements that substantially slow down aging by reducing peptide deficiency and restoring cell peptide-protein cycles in the body. There are 19 natural peptide products and 12 synthesized ones that cover almost every body system and organ. Thus, if you want to live longer being mentally and physically healthy you have now a real solution.

You can purchase original Khavinson peptide bioregulators from the official US distributor below.

Peptide Regulation of Ageing

Introduction

For many years a phenomenon of ageing had been studied within the framework of ethics and social issues. Only in the last century the society realized that a process of ageing should be studied from a different viewpoint, that is, as a special physiologic mechanism bearing a certain evolutionary significance.
Ageing is the most complicate issue in medicine and biology. The process of ageing is a gradual involution of tissues and development of organism malfunctioning. Its symptoms appear already at the end of the reproductive period and become more pronounced with ageing.

At the end of the XIX century I.I. Metchnikov showed that enhancement of cellular immunity contributed to a lifespan increase. He developed a phagocytic theory of immunity and considered human organism capable of combating pathologic ageing [1]. In 1908 he was awarded the Nobel Prize in Physiology or Medicine together with Paul Ehrlich. And only one century later, Peter Doherty and Rolf Zinkernagel conducted detailed studies in specificity of cellular immunity in case of viral infection (the Nobel Prize in Physiology or Medicine 1996).

The development of genetics and molecular biology required profound biochemical studies. Many years of scientific work by Marshall Nirenberg and Gobind Khorana resulted in deciphering genetic code and defining codons (triplets of nucleotides) for each of twenty amino acids (the Nobel Prize in Physiology or Medicine, together with Robert Holley, 1968). Fundamental investigation in nucleic acids biochemistry and identification of RNA and DNA bases sequence were conducted in the 60-70ies of the XX century by Paul Berg, Walter Gilbert and Frederick Sanger (the Nobel Prize in Chemistry, 1980).

Experimental and clinical studies in gerontology evidenced that immunity of the organism is among the first systemic functions to reveal disorders with ageing [2, 3]. Thymus peptide extracts and peptides, isolated from these extracts, were the first preparations suggested for immune deficit correction [4, 5, 6]. The origin of small regulatory peptides pool in a young organism became evident after the discovery of ubiquitin-mediated protein degradation in proteasomes made by Aaron Ciechanover, Avram Hershko, Irwin Rose (The Nobel Prize in Chemistry, 2004). Small peptides were shown to play an important role for transmission of biologic information, as for example autocrine hormones and neuropeptides do. A high molecular protein can be hydrolyzed in different ways, degradating into several small peptides. Due to this mechanism there can be produced peptides with completely different biologic functions as compared to the maternal macromolecule [7]. American mathematician Samuel Karlin proved in his works that there are several types of recurring blocks of amino acid residues with charged side chains in protein macromolecules. Structures of transcription factors reliably contain the greatest number of such blocks [8]. In 1961 Francois Jacob and Jacques Monod suggested a model of genetic regulation of protein synthesis with the participation of low-molecular ligand, which ousts repressor and triggers allosteric conformational transition in the DNA structure of bacterial cell [9]. In 1965 they were awarded the Nobel Prize in Physiology or Medicine along with Andry Lwoff.

However, the regulating role of small peptides had never been discussed in the concepts of gene control of protein synthesis in higher organisms before we started the research. Alongside with immunity decrease associated with age there occur other alterations at cellular level. In particular there take place changes in the inner structure of cellular nucleus. DNA-protein complex of cellular nucleus (chromatin) organizes into chromosomes only in case of cell division. In stationary state chromatin is found in two forms: euchromatin and heterochromatin [10]. Heterochromatin is usually localized in the nucleus periphery and contains generally inactive part of genome: genes blocked by repressors. The ratio euchromatin/heterochromatin changes with ageing due to reduction of active euchromatin. This leads to the decrease of protein synthesis in a cell [11]. Thus ageing phase of the organism reveals several levels of disfunction and may be classified as a systemic syndrome. Promising results of immunodeficiency correction by endogenous regulatory peptides testified the necessity of further enhanced studies [4,5].

Discovery of peptide regulation of ageing

It is known that specific limit of animal and human lifespan is approximately 30-40% higher than their mean lifespan. It could be referred to the impact of adverse factors causing changes in the gene structure and expression accompanied by disorders in the protein synthesis and organism functioning (Fig. 1).

Fig.1

Fig. 1. Potential increase in the average human lifespan up to the specific limit (biological reserve).
At the beginning of the 1970ies we studied the mechanism of immunodepression both experimentally and clinically. We found out that with ageing there takes place an involution of the central organ of immune system – thymus (Fig. 2, 3) and that of the neuroendocrine system – pineal gland. We also registered definite decrease of protein synthesis in cells of different organism tissues (Fig. 4).

Subcapsular cortex area (open biopsy, a 2-year old child).
A – hematoxylin and eosin staining;
B – thymic polypeptides fluorescence in the bodies and processes of epithelial cells forming Klark’s alveoli, as well as granules on the thymocyte membranes inside alveoli.

Subcapsular cortex area (open biopsy, a 2-year old child).
A – hematoxylin and eosin staining;
B – thymic polypeptides fluorescence in the bodies and processes of epithelial cells forming Klark’s alveoli, as well as granules on the thymocyte membranes inside alveoli.

Fig. 2. Age-related involution of thymus (indirect immunofluorescent method with antibodies to thymic polypeptides, x600).

Fig. 3. Expression of transcription proteins (PAX 1) in human thymus epithelial cells (the study was conducted in cooperation with Prince Philippe Biomedical Research Center, Valencia, Spain).

Fig. 4. Protein synthesis in hepatocytes of rats of different age.
To restore functions of thymus, pineal gland and other organs we developed a special method for isolation, refinement and fractionating of low-molecular peptides from extracts of these organs [12, 13]. Low-molecular peptides isolated from thymus (preparation Thymalin) and pineal gland (preparation Epithalamin) of animals were studied in different biologic models. These peptide preparations contributed to a reliable increase in animals mean lifespan in numerous experiments (Fig. 5) [12, 13, 14, 15, 16, 17]. Of particular importance is a correlation between mean lifespan and the main index of cellular immunity (reaction of blast-transformation of lymphocytes with phytohaemagglutinin) determining T lymphocytes function (Fig. 6) [14].

Fig. 5. The increase in the average lifespan up to the specific limit after peptide preparations application (mean results after 15 experiments).

Fig. 6. Peptide preparations effect on mean lifespan and reaction of blast-transformation of lymphocytes with phytohaemagglutinin in mice.
A significant increase in the mean lifespan of animals was evidently caused by a reliable antitumoral activity (Fig. 7) of low-molecular peptides isolated from thymus and pineal gland [14, 15, 17, 18, 19].

Fig. 7. Effect of pineal gland preparation on the frequency of tumor incidence in animals.
Small peptides isolated from different organs and tissues as well as their synthesized analogues (di-, tri-, tetrapeptides) revealed a realiable tissue specific (gene specific) effects both in cellular cultures and in experimental in young and old animals (Fig. 8).

Fig. 8. Peptide tissue-specific (gene-specific) regulation.
Peptide tissue specific activity manifested in stimulation of protein synthesis in cells of those organs they had been isolated from. The enhancement of protein synthesis under the effect of peptide has been registered in young and old animals (Fig. 9).

Fig. 9. Effect of the liver and pineal peptide preparations on protein synthesis intensity in hepatocyte monolayer culture in rats of different age
Especially significant appeared restoration of reproductive function system in old female rats subjected to the pineal peptide treatment (Fig. 10) [13]. Estrus phase in animals, analogous to menopause in women, lowered from the initial 95% down to 52% after the preparation administration, while other phases of the cycle, typical of the normal estrus, increased from the initial 5% up to 48%. It should be emphasized that in a special experiment initially none of the rats got pregnant after mating. Repeated mating after the administration of the pineal gland peptide entailed pregnancy in 4 out of 16 animals which gave birth to 5-9 healthy off-springs each.

Fig. 10. Effect of peptide preparation of the pineal gland on constant estrus in old female rats.
Thus there were ascertained main advantages of low-molecular peptides: they possessed high biologic activity, revealed tissue specificity and were neither species specific nor immunogenic. These features make regulatory peptides similar to peptide hormones [16, 20, 21].
A detailed study of molecular weight, chemical properties, amino acid composition and sequence of low-molecular peptides isolated from thymus, pineal gland and other organs had been carried out for many years [22, 23, 24, 25, 26]. The obtained data were used for chemical synthesis of several small peptides. A comparative analysis showed that biological activity of natural and synthetic preparations was largely identical. Thus, for example, thymus dipeptide stimulated immunity [24, 25]. Biological activity of natural and synthetic peptides appeared to be similar in standard testing in tissue cultures and in animals [27, 28, 29, 30]. These results demonstrate prospects for application of these peptides as geroprotectors [31, 32, 33]. The necessity of searching for new drugs – geroprotectors dictated the onset of preclinical studies of these preparations on different structural levels.

On the level of the organism in different animals we have registered a significant variety of biologic effects exerted by small peptides especially by peptides of thymus and pineal gland, including proliferative activity and apoptosis [34, 35, 36, 37, 38, 39, 40, 41, 42].

On the level of cellular structures, small peptides activate heterochromatine in the cell nuclei in senile patients (Table 1) [11, 43].

As it was said above there are two forms of chromatin in the cellular nucleus: light euchromatin and dense heterochromatin located near nuclear membrane. Gene transcription takes place in the light phase, that’s in euchromatin. With ageing the amount of heterochromatin in the nucleus increases on average from 63% to 80%. Regulatory peptides entail the increase in the amount of euchromatin in the nucleus. This means that more genes become available for transcription factors, and transcription of gene information goes on more intensively as well as protein synthesis. In other words the more euchromatin there is in the nucleus the more intensive the protein synthesis in the cell is [10, 11, 43].

The capability of peptides to induce polypotential cells differentiation is of special significance (Fig. 11) [42]. Thus addition of retinal peptides to polypotential cells of Xenopus laevis early gastrula ectoderm led to the emergence of retinal and pigment epithelium cells. This outstanding result explains a pronounced clinical effect of the preparation of the retina in patients with retinal degenerations [42] and in animals with genetically determined retinitis pigmentosa.

Fig. 11. Induction effect of retinal peptides on the polypotent cells of Xenopus laevis early gastrula ectoderm.

On a chromosome level the number of chromosomes aberrations was used a marker of DNA damages in an ageing organism. Somatic mutations can occur due to accumulation of stable aberrations and underlie age-related pathology, including malignant neoplasia. Reliable antimutagenic and reparative activity of thymus and pineal gland peptides have been confirmed by a reduction in the number of chromosome aberrations in the bone marrow cells and cornea epithelium cells in animals revealing accelerated ageing [45].

On the level of gene activity regulation it was established that administration of peptides Lys-Glu and Ala-Glu-Asp-Gly to transgenic mice caused a 2–3.6-fold suppression of HER-2/neu gene expression (human breast cancer) as compared to the control group. This suppression is accompanied by a reliable reduction of the tumor diameter (Fig. 12) [41].

Fig. 12. Peptides effect on the development of mammary adenocarcinoma and HER-2/neu oncogene expression in transgenic mice (the study was conducted in cooperation with the National Research Centre on Ageing, Ancona, Italy).

It was revealed that addition of tetrapeptide Ala-Glu-Asp-Gly to the cultural medium of human lung fibroblasts induces telomerase gene expression and contributes to a 2.4-fold lengthening of telomeres. Activation of gene expression is accompanied by a growing number of cellular divisions (by 42.5%), which is the evidence of Hayflick’s limit overcoming (Fig. 13) [46, 47].

The effect of di- and tetrapeptides Lys-Glu, Glu-Trp, Ala-Glu-Asp-Gly, Ala-Glu-Asp-Pro on the expression of 15 247 murine heart and brain genes before and after peptides administration was studied with the employment of DNA-microarray technology [48]. In this experiment, there were used clones from the library of the National Institute on Ageing, USA. This experiment provided unique data on alteration in the expression of different genes under the effect of peptide preparations (Fig. 11). An important conclusion driven from the experiment was that every peptide specifically regulates particular genes. Results of this experiment testify to the existing mechanism of peptide regulation of gene activity. It was also registered that dipeptide Lys-Glu, showing immunomodulating activity, regulates gene interleukin-2 expression in blood lymphocytes [49].

Fig. 13. Overcoming human somatic cell division limit due to introduction of the peptide into the culture of the pulmonic fibroblasts.

Fig. 14. Peptide effect on gene expression in the heart of mice (the study was conducted in cooperation with the National Institute on Aging, Baltimore, USA).

On the molecular level, there was an obvious gap between multiple evidence of specific effects, caused by regulatory peptides in activation of gene transcription [50, 51, 52, 53, 54, 55, 56, 57, 58], and limited schemes of the process underlying the selective binding of the transcription factor with specific DNA sites. Meanwhile non-specific binding of proteins with the DNA double helix was proved using physicochemical methods [59]. Activation of gene transcription in cells of higher organisms as a rule needs dozens of macromolecular activators and transcription factors.

We proposed a molecular model of interaction between regulatory peptides and DNA double helix in gene promoter region of (Fig. 15, 16, 17, 18) [60, 61].

Fig. 15. Unfolded peptide Ala-Glu-Asp-Gly conformation (plan projection). There are shown end and side functional groups, capable of complementary interaction with DNA.
—NH3 – proton donors groups;
=O – proton acceptors groups;
—CH3 – hydrophobic (methyl) group.
Bold line – main peptide chain.

Fig. 16. Metric location of functional groups exposed onto the surface of the DNA major groove in case of embedding of each nucleotide pair into DNA double helix. Dash line – perpendicular plane, where aromatic structures of nucleic bases are located.
—NH2 – proton donors groups;
=7N – proton acceptors groups;
—CH3 – hydrophobic (methyl) group.

Fig. 17. Sequence of nucleotide pairs in the DNA double helix, functional groups of which are complimentary to functional groups of Ala-Glu-Asp-Gly peptide. This sequence is many times repeated on the promoter segment of telomerase gene.

Fig. 18. Scheme of complementary interaction of tetrapeptide Ala-Glu-Asp-Gly with DNA double helix (“DNA-tetrapeptide” complex on the promoter segment of telomerase gene).
Geometrical and chemical complementarity of peptide amino acid sequence and DNA nucleotide pairs sequence was assumed as a basis for the molecular model. Regulatory peptide recognizes a specific site in the DNA double helix if its own amino acid sequence is complementary to the DNA nucleotide sequence for a sufficient length. In other words their interaction is specific due to matching sequences.
Each sequence of the DNA double helix nucleotide pairs forms a unique pattern of functional groups on the surface of the DNA double helix major groove. A peptide in the unfolded β-conformation can complimentary fit into the in the DNA major groove along the double helix axis. We used data on molecular geometry of the DNA double-helix and peptide β-thread from scientific publications in order to identify nucleotide pairs sequence for specific binding of the DNA and peptide Ala-Glu-Asp-Gly. The screening conducted showed that this tetrapeptide can be located in the DNA major groove with the ATTTG (or ATTTC) nucleotide sequence on the main chain in compliance with the complementarity of disposition of their functional groups [59].

For experimental testing of the molecular model there were used synthetic preparations: DNA [poly(dA-dT):poly(dA-dT)] (double helix) and tetrapeptide Ala-Glu-Asp-Gly. Gel chromatography helped to prove that peptide Ala-Glu-Asp-Gly forms stable intermolecular complex with the DNA double helix (Fig. 19) [61].

1 – individual Ala-Glu-Asp-Gly peptide
2 – free DNA double helix [poly (dA-dT) : poly (dA-dT)]
3 – mixture of peptide and DNA
Fig. 19. HPLC of peptide and DNA on sefadex G-25 in physiological solution at room temperature.
Complementary binding of the peptide with nucleotides sequence on the leading strand TATATA of the double helix can be conducted by six hydrogenous and one hydrophobic bonds between functional groups of the both participants.
Under normal physiological conditions DNA exists in the form of a double helix two polymeric chains of which are kept together by hydrogenous bindings between pairs of bases of each chain. Most of the biological processes with DNA participation (transcription, replications) need the double helix to undergo disjunction into separate strands. In particular, it is known, that local separation of double helix strands precedes gene transcription by RNA polymerase. For the transcription onset (synthesis of the matrix RNA) the DNA double helix has to be freed from histones, and in the place where the matrix RNA synthesis starts, the strands of the double helix should be disintegrated (Fig. 20).

Fig. 20. The scheme of local separation of strands [poly (dA-dT) : poly (dA-dT)] as a result of peptide Ala-Glu-Asp-Gly binding in DNA double helix major groove.
Concentration dependent hyperchromic effect (increased optic density 260 nm) was found by spectrophotometery of solutions containing synthetic DNA double helix and tetrapeptide Ala-Glu-Asp-Gly. The hyperchromic effect points out a partial destruction of hydrogen bonds between nucleotide pairs of the double helix and local separation of its strands (allosteric conformational changes) [61].

It was experimentally revealed that detachment (melting) of free DNA strands occurs at the temperature +69.50С. In the “DNA-tetrapeptide” system melting of the double helix occurred at the temperature +28°С and was characterized by approximately 2-fold decrease in the values of entropy and enthalpy. This fact points out a thermodynamically simplified way of the DNA strands separation in temperature settings typical of biochemical processes of the majority of living organisms. In vitro experiments show that a small peptide of the definite structure and amino acid sequence can participate in activation of genes transcription on the stage of strands disjunction in the DNA double helix. Biochemical aspect of this phenomenon consists in similarity of structure and amino acid sequence of a regulatory peptide and a specific segment of the peptide chain of the macromolecular transcription factor.

Thus, the studies of peptides biological activity on different structural levels and of physicochemical processes of their interaction proved an indubitably high physiologic activity of peptide regulators. Major conclusion reads that peptides are capable of regulating gene expression. Pre-clinical trials demonstrated high biological activity and safety of synthesized peptides [61, 63, 64, 65]. Thus, the administration of peptides Lys-Glu, Ala-Glu-Asp-Gly to animals contributes to a reduced incidence of tumors and an increase of mean lifespan [66, 67, 68]. Peptide Ala-Glu-Asp-Pro stimulates nerve regeneration [69], peptide Lys-Glu-Asp-Trp decreases blood glucose level in animals with experimental diabetes mellitus [70].

Taking into consideration a reliable biological activity of peptides we found it reasonable to study the effect of regulatory peptides in monkeys. Restoration of the melatonin level up to normal following the administration of the peptide preparation to old monkeys was among our significant achievements.

Fig. 21. The peptide effect on melatonin production in monkeys of different age.
The same old monkeys revealed a restoration to normal indices of a daily rhythm of secretion of the main hormone of adrenal gland – cortisol (Fig. 22).

Fig. 22. The peptide effect on cortisol production in monkeys of different age (in the morning and in the evening).

Taking into consideration the encouraging data testifying to high geroprotective activity of both natural tissue specific and synthetic peptide preparations we have been concentrating our attention on studies of geroprotective activity of peptides in old and senile people in recent years [42, 57, 71, 72, 73, 74, 75, 76]. Thus, annual treatment course with thymus and pineal preparations led to a reliable decrease in mortality (Table 2), due to improvement of brain function and that of immune, endocrine, cardio-vascular systems, increased density of osseous tissue (Fig. 23, 24) [42, 57, 71, 72]. It is noteworthy that application of preparation of the thymus led to a 2-fold decrease in frequency of acute respiratory disease (Fig. 25) [57]. The restoration of melatonin secretion level in patients subjected to administration of preparation of the pineal gland is of special significance (Fig. 26) [71, 71]. These results suggest good prospects for tackling demographic issues [77].

Fig. 23. Effect of thymus preparation on metabolism in elderly patients (60-74 y.o.).

Fig. 24. Dynamics of reaction of blast-transformation of lymphocytes with phytohaemagglutinin index in elderly patients in 3 years after 6 courses of peptide preparations.

Fig. 25. ARD incidence in elderly and old people treated with thymus preparation

Fig. 26. Effect of the pineal gland preparation on melatonin level in elderly people.

Conclusion

The mechanisms of ageing studies showed that an involution of the main organs and tissues of the organism accompanied by a decrease of protein synthesis in cells underlies the process of ageing.
Peptide preparations isolated from organs of young animals when introduced into an old organism are capable of inducing protein synthesis, followed by restoration of the main functions.

It was registered that long-term application of peptides, both isolated from the organs and synthesized from the amino acid, in animals (as a rule starting from the second half of their life) leads to a reliable increase in their mean lifespan by 20-40% and reaching a specific limit.
It was revealed that small peptides (di-, tri- and tetrapeptides) are capable of complementary interaction with the DNA specific binding site on the promoter segment of genes, inducing disjoining of double helix strands and RNA polymerase activation. Discovery of the phenomenon of peptide activation of gene transcription points out the natural mechanism of organism to maintain physiologic functions, which is based on the complementary interaction of the DNA and regulatory peptides. This process is fundamental for the development and functioning of the living substance (Fig. 27, 28), while ageing is an evolutionary determined biologic process of age-related changes in gene structure and expression. Application of peptide bioregulators in humans for preventive purposes led to a significant rehabilitation of the main physiological functions and a reliable mortality decrease in different age groups during the period of 6-12 years.

Fig. 27. The role of peptides in the cycle of DNA, RNA and protein biosynthesis.
It should be emphasized that this approach to the prevention of ageing is based not only on experimental and clinical data, but also on technological developments having world novelty [78, 79, 80, 81, 82].
The author and his group believe that the whole complex of 35-year experimental and clinical studies may serve a vital contribution to the advancement of a scientific heritage of the prominent Russian scientist I.I. Mechnikov in the field of gerontology and will be to the benefit of people, especially for those of old and old old age

Acknowledgement

The author expresses his sincere gratitude to: Academicians of the Russian Academy of Sciences and of the Russian Academy of Medical Sciences A.I. Grigoriev, M.A. Paltsev, R.V. Petrov; Academicians of the Russian Academy of Sciences V.T. Ivanov, S.G. Inge-Vechtomov, A.D. Nozdrachev; Academicians of the Russian Academy of Medical Sciences V.G. Artamonova, I.P. Ashmarin, N.P. Bochkov, F.I. Komarov, E.A. Korneva, B.A. Lapin, G.A. Sofronov, K.V. Sudakov, B.I. Tkachenko, V.A. Tutelyan, Academicians of the Academy of Medical Sciences of Ukraine O.V. Korkushko and G.M. Butenko, Associate Members of the Russian Academy of Sciences D.P. Dvoretskiy, Associate Members of the Russian Academy of Medical Sciences G.M. Yakovlev, Professors V.N. Anisimov, A.V. Arutjunian, B.I. Kuznik, L.K. Shataeva, researchers of the Saint Petersburg Institute of Bioregulation and Gerontology of the North-Western Branch of the Russian Academy of Medical Sciences Professors I.M. Kvetnoy, V.V. Malinin, V.G. Morozov, G.A. Ryzhak, distinguished doctor of the Russian Federation L.V. Kozlov, doctors E.I. Grigoriev Ph.D., S.V. Anisimov Ph.D., I.E. Bondarev Ph.D., O.N. Mikhailova Ph.D., A.A. Chernova, and foreign colleagues Professors T.A. Lezhava (Georgia), A.I. Yashin (USA), J. Atzpodien (Germany), K.R. Boheler (USA), C. Franceschi (Italy), E. Lakatta (USA), J. Martinez (France), M. Passeri (Italy) for their significant contribution into our research work.

You can purchase original Khavinson peptide bioregulators from the official US distributor below.

References

  1. Mechnikov I. Etudes sur la nature humaine: essai de philosophie optimiste. Paris : Masson, 1903. 399 p.
  2. Bellamy D. The thymus in relation to problems of cellular growth and aging // Gerontologia. – 1973. – V.19. – P.162-184.
  3. Hirokawa K. The thymus and aging // Immunology and aging. New York; London, – 1977. – P. 51-72.
  4. Goldstein G., Scheid M., Hammerling U. et al. Isolation of a polypeptide that has Lymphocyte-differentiating properties and is probably represented universally in living cells // Proc. Natl. Acad. Sci. USA. – 1975. – V. 72, N 1. – P.11-15.
  5. Hannappel E., Davoust S., Horecker B.L. Thymosin β8 and β9: Two new peptides isolated from calf thymus homologous to thymosin β4 // Proc. Natl. Acad. Sci. USA. – 1982. – V. 82. – P. 1708–1711.
  6. Audhya T., Scheid M. P., Goldstein G. Contrasting biological activities of thymopoietin and splenin, two clously related polypeptide products of thymus and spleen // Proc. Natl. Acad. Sci. USA. – 1984. – V. 81, N. 9. – P. 2847–2849.
  7. Ivanov V.T., Karelin A.A., Philippova M.M. et al. Hemoglobin as a source of endogenous bioactive peptides: the concept of tissue-specific peptide pool // Biopolymers. – 1997. – V. 43, N 2. – P. 171–188.
  8. Karlin S., Altschul S.F., Method for assessing the statistical significance of molecular sequence features by using general scoring schemes. // Proc. Natl. Acad. Sci. USA, – 1990, – V. 87, N 6, – P. 2264 – 2268.
  9. Jacob F., Monod J. Genetic regulation mechanisms in the synthesis of proteins // J. Mol. Biol. – 1961. – V.3. – P. 318–356.
  10. Lezhava T. Heterochromatization as a key factor in aging. // Mech. Ageing Dev., – 1984, – V.28. N 2-3, – P. 279 – 288.
  11. Lezhava T. Human chromosomes and aging.From 80 to 114 Years./ Nova Biomedical. – 2006. – New York., – 177 p.
  12. Dilman V.M., Anisimov V.N., Ostroumova M.N., Morozov V. G., Khavinson V. Kh., Azarova M.A. Study of the anti-tumor effect of polypeptide pineal extract // Oncology. – 1979. – Vol.36, №6. – P. 274-280.
  13. Dilman V.M., Anisimov V.N., Ostroumova M.N., Khavinson V. Kh., Morozov V. G. Increase in lifespan of rats following polypeptide pineal extract treatment // Exp. Pathol. – 1979. – Bd. 17, №9. – P. 539 – 545.
  14. Anisimov V.N., Khavinson V. Kh., Morozov V. G. Carcinogenesis and aging. IV. Effect of low-molecular-weight factors of thymus, pineal gland and anterior hypothalamus on immunity, tumor incidence and lifespan of C3H/Sn mice // Mech.Ageing Dev. – 1982. – Vol.19. – P. 245 – 258.
  15. Anisimov V.N., Loktionov A.S., Khavinson V. Kh., Morozov V. G. Effect of low-molecular-weight factors of thymus and pineal gland on lifespan and spontaneous tumour development in female mice of different age // Mech. Ageing Dev. – 1989. – Vol.49. – P. 245 – 257.
  16. Аnisimov V.N., Bondarenko L.A., Khavinson V. Kh. The pineal peptides: interaction with indoles and the role in aging and cancer // Neuro-endocrinology: New Frontiers. -London, Tьbingen. – 1990. – P. 317 – 325.
  17. Anisimov V.N., Bondarenko L.A., Khavinson V. Kh. Effect of pineal peptide preparation (epithalamin) on lifespan and pineal and serum melatonin level in old rats // Ann. N.Y. Acad. Sci. – 1992. – V. 673. – P 53-57.
  18. Vaskovsky B.V., Kishinevski R.N., Mikhaleva I.I., Ivanov V.T., Khavinson V. Kh., Morozov V.G., Mikhaltsov A.N., Anisimov V.N. Bioactive peptides from bovine pineal gland and bone marrow extracts. In: «Chemistry of Peptides and Proteins» DWI Report: Aachen. – 1993. – Vol.5/6, Part B. – P.308-316.
  19. Anisimov V.N., Khavinson V. Kh., Morozov V. G. Twenty years of study on effect of pineal peptide preparation: epithalamin in experimental gerontology and oncology // Ann. N.Y. Acad. Sci. – 1994. – Vol.719. – P. 483 – 493.
  20. Alexandrov V.A., Bespalov V.G., Morozov V.G., Khavinson V. Kh., Anisimov V.N. Study of the post-natal effects of chemopreventive agents on ethylnitrosourea-induced transplacental carcinogenesis in rats. II. Influence of low-molecular-weight polypeptide factors from the thymus, pineal glands, bone marrow, anterior hypothalamus, brain cortex and brain white substance // Carcinogenesis. – 1996. – Vol.17, N 8. – P. 1931-1934.
  21. Anisimov V.N., Mylnikov S.V., Oparina T.I., Khavinson V. Kh. Effect of melatonin and pineal peptide preparation epithalamin on lifespan and free radical oxidation in Drosophila melanogaster // Mech.Ageing Dev. – 1997. – Vol. 97. – P. 81-91.
  22. Morozov V.G., Khavinson V. Kh. US Patent N 5,070,076 «Thymus-Gland preparation and method for producing same»; 03.12.1991.
  23. Pisarev O.A., Morozov V. G., Khavinson V. Kh., Shataeva L.K., Samsonov G.V. Isolation, physico-chemical and biological propepties of the immunity polypeptide bioregulator from thymus // Chemistry of Peptides and Proteins. – Berlin, New York. – 1982. – Vol. 1. – P. 137 – 142.
  24. Morozov V.G., Khavinson V. Kh. US Patent N 5,538,951 «Pharmaceutical preparation for the therapy of immune deficiency conditions»; 23.07.1996.
  25. Morozov V.G., Khavinson V. Kh. US Patent N 6,136,788 «Pharmaceutical preparation for the therapy of immune deficiency conditions»; 24.10.2000.
  26. Morozov V.G., Khavinson V. Kh. Natural and synthetic thymic peptides as therapeutics for immune dysfunction // Int.J. Immunopharmacology. – 1997. – Vol. 19, N 9/10. – P 501-505.
  27. Anisimov V.N., Khavinson V. Kh., Morozov V.G. Effect of synthetic dipeptide ThymogenТ (Glu-Trp) on lifespan and spontaneous tumor incidence in rats // The Gerontologist. – 1998. – Vol. 38. – P. 7-8.
  28. Anisimov V.N., Mylnikov S.V., Khavinson V. Kh. Pineal peptide preparation epithalamin increases the lifespan of fruit flies, mice and rats // Mech. Ageing Dev. – 1998. – Vol. 103. – P. 123-132.
  29. Anisimov V.N., Khavinson V. Kh., Morozov V.G. Immunomodulatory peptide L-Glu-L-Trp slows down aging and inhibits spontaneous carcinogenesis in rats // Biogerontology. – 2000. – V. 1. – P. 55-59.
  30. Khavinson V. Kh., Chalisova N.I., Okulov V.B. The neurite-stimulating effect of peptides from brain in dorsal root ganglion neuron organotypic culture // Prim. Sensory Neuron. – 1997. – Vol. 2, N 3. – P. 191-200..
  31. Khavinson V. Kh., Solovieva D.V. New approach to the prophylaxis and treatment of age-related pathology // Romanian J. of Gerontology and Geriatrics. – 1998. – Vol. 20, N 1. – P. 28-34.
  32. Kvetnoy I.M., Reiter R.J., Khavinson V. Kh. Claude Bernard was right: hormones may be produced by “non-endocrine” cells // Neuroendocrinology Lett. – 2000. – Vol. 21. – P. 173-174.
  33. Khavinson V. Kh. US Patent N 6,727,227 B1 «Tetrapeptide revealing geroprotective effect, pharmacological substance on its basis, and the method of its application»; 27.04.2004.
  34. Khavinson V. Kh., Myl’nikov S.V. Effect of pineal tetrapeptide on antioxidant defense in Drosophila melanogaster // Bulletin Exp. Biol. Med. (Rus.) – 2000. – Vol. 129, № 4. – P. 355 – 356.
  35. Khavinson V. Kh., Izmailov D.M., Obukhova L.K., Malinin V.V Effect of epitalon on the lifespan increase in Drosophila melanogaster // Mech. Ageing Dev. – 2000. –V. 120. – P. 141–149.
  36. Anisimov V.N., Arutjunyan A.V., Khavinson V. Kh. Effects of pineal peptide preparation Epithalamin on free-radical processes in humans and animals // Neuroendocrinology Lett. – 2001. – Vol. 22. – P. 9-18.
  37. Anisimov V.N., Khavinson V. Kh., Mikhalski A.I., Yashin A.I. Effect of synthetic thymic and pineal peptides on biomarkers of ageing, survival and spontaneous tumour incidence in female CBA mice // Mech. Ageing Dev. – 2001. – V. 122, N. 1. – P. 41-68.
  38. Khavinson V. Kh., Goncharova N., Lapin B. Synthetic tetrapeptide epitalon restores disturbed neuroendocrine regulation in senescent monkeys // Neuroendocrinology Lett. – 2001. – V. 22. – P. 251-254.
  39. Khavinson V. Kh., Morozov V.G., Anisimov V.N. Experimental studies of the pineal gland preparation Epithalamin. – The pineal gland and cancer. – Bartsch C., Bartsch H., Blask D.E., Cardinali D.P., Hrushesky W.J.M., Mecke D. (Eds.) – Springer-Verlag Berlin Heidelberg. – 2001. – P. 294-306.
  40. Anisimov V.N., Khavinson V. Kh., Popovich I.G., Zabezhinski M.A. Inhibitory effect of peptide Epitalon on colon carcinogenesis induced by 1,2-dimethylhydrazine in rats // Cancer Lett. – 2002. – V. 183. – P. 1-8.
  41. Anisimov V.N., Khavinson V. Kh., Provinciali M., Alimova I.N., Baturin D.A., Popovich I.G., Zabezhinski M.A., Imyanitov E.N., Mancini R., Franceschi C. Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in Her-2/NEU transgenic mice // Int. J. Cancer. – 2002. V. 101. – P. 7-10.
  42. Khavinson V. Kh. Peptides and ageing. – Neuroendocrinology Letters. – Special Issue, 2002. – 144 p.
  43. Khavinson V. Kh., Lezhava T.A., Monaselidze J.R., Jokhadze T.A., Dvalis N.A., Bablishvili N.K., Trofimova S.V. Peptide Epitalon activates chromatin at the old age // Neuroendocrinology Lett. – 2003. – V. 24. N. 5 – P. 329-333.
  44. Khavinson V. Kh., Razumovsky M., Trofimova S., Grigorian R., Razumovskaya A. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa // Neuroendocrinology Lett. – 2002. – V. 23. – P. 365-368.
  45. Anisimov V.N., Popovich I.G., Zabezhinski M.A., Rosenfeld S.V. Spontaneous mutagenesis, carcinogenesis and aging in SAM mice: effect of melatonin, epitalon and neuronal // Proceedings of the 19th SAM meeting. – Ed. T.Takeda. Kyoto. – 2004. – P. 101-102.
  46. Khavinson V. Kh., Bondarev I., Butyugov A. Epitalon peptide induces telomerase activity and telomere elongation in human somatic cells. // Bulletin Exp. Biol. Med. (Rus). – 2004. – V. 135. N. 6. – P. 590-592.
  47. Khavinson V. Kh., Bondarev I., Butyugov A., Smirnova T. Peptide promotes overcoming of the division limit in human somatic cell // Bulletin Exp. Biol. Med. (Rus). – 2004. – V. 137. N. 5. – P. 613-616.
  48. Anisimov S.V., Boheler K.R., Khavinson V. Kh., Anisimov V.N. Elucidation of the effect of brain cortex tetrapeptide Cortagen on gene expression in mouse heart by microarray // Neuroendocrinology Lett. – 2004. – V. 25. N. 1/2. – P. 87-93.
  49. Khavinson V. Kh., Morozov V.G., Malinin V.V., Kazakova T.B., Korneva E.A. Effect of peptide Lys-Glu on Interleukin-2 gene expression in lymphocytes // Bulletin Exp. Biol. Med. (Rus.) – 2000. – Vol. 130, № 9. – P. 898–899.
  50. Khavinson V. Kh., Korneva E.A., Malinin V.V., Rybakina E.G., Pivanovich I.Yu., Shanin S.N. Effect of epitalon on interleukin-1Я signal transduction and the reaction of thymocyte blast transformation under stress // Neuroendocrinology Lett. – 2002. – V. 23. N. 5/6. – P. 411-416.
  51. Khavinson V. Kh., Rybakina E.G., Malinin V.V., Pivanovich I.Yu., Shanin S.N., Korneva E.A. Effects of Short Peptides on Thymocyte Blast Tpansformation and Signal Transduction along the Sphingomyelin Pathway // Bulletin Exp. Biol. Med. (Rus). – 2002. – V. 133, N. 5. – P. 497-499.
  52. Sibarov D.A., Kovalenko R.I., Malinin V.V., Khavinson V. Kh. Epitalon influences pineal secretion in stress-exposed rats in the daytime // Neuroendocrinology Lett. – 2002. – V. 23. – P. 452-454.
  53. Anisimov V.N., Khavinson V. Kh. Small peptide-associated modulation of aging and longevity. // Modulating aging and longevity. – Kluwer Academic Publishers (Printed in Great Britain) – S.I.S.Rattan (ed.). – 2003. – P. 279-301.
  54. Anisimov V.N., Khavinson V. Kh., Popovich I.G., Zabezhinski M.A., Alimova I.N., Rosenfeld S.V., Zavarzina N.Yu., Semenchenko A.V., Yashin A.I. Effect of epitalon on biomarkers of aging, lifespan and spontaneous tumor incidence in female swiss-derived SHR mice // Biogerontology. – 2003. – N 4. – P.193-202.
  55. Djeridane Y, Khavinson V. Kh., Anisimov V.N., Touitou Y. Effect of synthetic pineal tetrapeptide (Ala-Glu-Asp-Gly) on melatonin secretion by the pineal gland of young and old rats // J.Endocrinol.Invest. – 2003. – Vol. 26, N 3. – P. 211-215.
  56. Kossoy G., Zandbank J., Tendler E., Anisimov V.N., Khavinson V. Kh., Popovich I.G., Zabezhinski M.A., Zusman I., Ben-Hur H. Epitalon and colon carcinogenesis in rats: proliferative activity and apoptosis in colon tumors and mucosa // Int. J. Mol. Med. – 2003. – V.12, N. 4. – P. 473-477.
  57. Khavinson V., Morozov V. Peptides of pineal gland and thymus prolong human life // Neuroendocrinology Lett. – 2003. – V. 24. N. 3/4. – P. 233-240.
  58. Labunets I.F., Butenko G.M., Khavinson V. Kh. Effect of bioactive factors of the pineal gland on thymus function and cell composition of the bone marrow and spleen in mice of different age // Bulletin Exp. Biol. Med. (Rus). – 2004. – V. 137. N. 5. – P. 620-622.
  59. Riadnova I.Yu., Shataeva L.K., Khavinson V. Kh. DNA-protein interaction studied in model systems // Polymer Science, Ser. A. – 2000. – V. 42, № 5. – P. 551-556.(Rus)
  60. Khavinson V., Shataeva L., Chernova A. DNA double-helix binds regulatory peptides similarly to transcription factors // Neuroendocrinology Lett. – 2005. – V. 26. N. 3. – P. 237-241.
  61. Khavinson V. Kh., Solovyov A.Yu, Shataeva L.K Molecular mechanism of interaction between oligopeptides and double-stranded DNA // Bulletin Exp. Biol. Med. (Rus). – 2006. – V. 141. N. 4. – P. 457-461.
  62. Khavinson V. Kh., Myl’nikov S.V. Effect of Epitalone on the age-specific changes in the time course of lipid peroxidation in Drosophila melanogaster // Bulletin Exp. Biol. Med. (Rus.) – 2000. – Vol. 130, № 11. – P. 1116–1119.
  63. Khavinson V. Kh. Tissue-specific effects of peptides // Bulletin Exp. Biol. Med. (Rus.) – 2001. – Vol. 132, № 2. – P. 807–808.
  64. Khavinson V. Kh., Myl’nikov S.V., Oparina T.I. Effect of peptides on generation of reactive oxygen species in subcellular fractions of Drosophila melanogaster // Bulletin Exp. Biol. Med. (Rus.) – 2001. – Vol. 132, № 1. – P. 682–685.
  65. Khavinson V. Kh., Egorova V.V., Timofeeva N.M., Malinin V.V., Gordova L.A. and Gromova L.V. Effect of Vilon and Epithalon on Glucose and Glycine Absorption in Various Regions of Small Intestine in Aged Rats // Bulletin Exp. Biol. Med. (Rus). – 2002. – V. 133. N. 5. – P. 494-496.
  66. Khavinson V. Kh., Anisimov V.N., Zavarzina N.Yu., Zabezhinskii M.A., Zimina O.A., Popovich I.G., Shtylik A.V., Malinin V.V., Morozov V.G. Effect of vilon on biological age and lifespan in mice // Bulletin Exp. Biol. Med. (Rus.) – 2000. – Vol. 130, № 7. – P. 687–690.
  67. Pliss G.B., Mel’nikov A.S., Malinin V.V., Khavinson V. Kh. Inhibitory effect of peptide vilon on the development of induced rat urinary bladder tumors in rats // Bulletin Exp. Biol. Med. (Rus.) – 2001. – Vol. 131, № 6. – P. 558–560.
  68. Vinogradova I.A, Bukalev A.V., Zabezhinski M.A., Semenchenko A.V., Khavinson V. Kh., Anisimov S.V. Effect of Ala-Glu-Asp-Gly peptide on lifespan and development of spontaneous tumors in female rats exposed to different illumination regimes // Bulletin Exp. Biol. Med. (Rus.) – 2007. – Vol. 144, № 6. – P. 825–830.
  69. Turchaninova L.N., Kolosova L.I., Malinin V.V., Moiseeva A.B., Nozdrachev A.D., Khavinson V. Kh. Effect of tetrapeptide Cortagen on regeneration of sciatic nerve // Bulletin Exp. Biol. Med. (Rus.) – 2000. – Vol. 130, № 12. – P. 1172–1174.
  70. Khavinson V. Kh., Gavrisheva N.A., Malinin V.V., Chefu S.G., Trofimov E.L. Effect of Pancragen on blood glucose level, capillary permeability and adhesion in rats with experimental diabetes mellitus // Bulletin Exp. Biol. Med. (Rus.) – 2007. – Vol. 144, № 4. – P. 559–562.
  71. Labunets I.F., Butenko G.M., Magdich L.V., Korkushko O.V., Khavinson V. Kh., Shatilo V.B. Effect of epithalamin on circadian relationship between the endocrine function of the thymus and meiatonin–producing function of the pineal gland in elderly people // Bulletin Exp. Biol. Med. (Rus). – 2004. – V. 137. N. 5. – P. 617-619 .
  72. Korkushko O.V., Khavinson V. Kh., Shatilo V.B., Magdich L.V. Effect of peptide preparation epithalamin on circadian rhythm of epiphyseal melatonin–producing function in elderly people // Bulletin Exp. Biol. Med. (Rus). – 2004. – V. 137. N. 4. – P. 389-391.
  73. Vladimir N.Anisimov, Vladimir Kh. Khavinson. Pineal peptides as modulators of aging // Aging interventions and therapies – World Scientific.- Suresh I S Rattan (ed.). – 2005. – P.127-146.
  74. Khavinson V. Kh., Malinin V.V. Gerontological aspects of genome peptide regulation // Basel (Switzerland): Karger AG, – 2005. – 104 p.
  75. Goncharova N.D., Vengerin A.A., Khavinson V. Kh., Lapin B.A. Pineal peptides restore the age-related disturbances in hormonal functions of the pineal gland and the pancreas // – Experimental Gerontology. – 2005. – V.40. – P. 51-57.
  76. Kozina L.S., Arutjunyаn A.V., Khavinson V. Kh. Antioxidant properties of geroprotective peptides of the pineal gland // Arch. Gerontol. Geriatr. Suppl. 1. – 2007. – P. 213-216.
  77. Khavinson V. Kh., Mikhailova O.N. Health and aging in Russia // Clobal health and global aging / (ed. by Mary Robinson et al.); foreword by Robert Butler. – L st ed. – 2007. – P. 226-237.
  78. Khavinson V. Kh., US Patent N 7,101,854 B2 «Tetrapeptide stimulating the functional activity of hepatocytes, pharmacological substance on its basis and the method of its application»; 05.09.2006.
  79. Khavinson V. Kh., Morozov V.G., Malinin V.V., Grigoriev E.I.; US Patent N 7,189,701 B1 «Tetrapeptide stimulating the functional activity of neurons, pharmacological agent based thereon and method of use thereof»; 13.03.2007.
  80. Khavinson V. Kh., Malinin V.V., Grigoriev E.I., Ryzhak G.A.; LV Patent N 13462 «Tetrapeptide regulating blood glucose level in diabetes mellitus»; 20.02.2007.
  81. Khavinson V. Kh., Ryzhak G.A., Grigoriev E.I., Ryadnova I.Yu.; EP Patent N 1 758 922 B1 «Peptide substance restoring function of respiratory organs»; 13.02.2008.
  82. Khavinson V. Kh., Ryzhak G.A., Grigoriev E.I., Ryadnova I.Yu.; EP Patent N 1 758 923 B1 «Peptide substance restoring myocardium function»; 13.02.2008.

Clinical Study Of Khavinson A-12 Chitomur Peptide

The dietary supplement Chitomur contains a complex of low-molecular peptides with molecular weight up to 5000 Da, isolated from the tissues of the urinary bladder wall of young animals – calves aged up to 12 months. Chitomur is manufactured in the form of tablets or capsules with a content of active substance 10 mg.

Experimental studies have shown that the peptides possess tissue-specific action on the cells of the tissues from which they were isolated. Chitomur peptides regulate metabolism processes in the urinary bladder wall cells, increase their safety margins, having a favorable effect on the organism adaptation processes in extreme conditions, the possess anti-oxidative properties, regulating peroxide oxidation processes in the urinary bladder wall tissues. So it is possible to extrapolate an efficiency of administration of Chitomur for restoration of the function of the urinary bladder and their disorders of various origin.

Among the disease most frequent in elderly persons there is one which considerably worsens quality of life of the patients and worsening a course of concomitant pathology, it is pathology of urine bladder. There are many elderly persons with various functional disorders of lower urinary tracts, especially – overactive bladder (OAB). The diagnosis is made when there is no hormonal, metabolic or other obvious diseases (urinary infection, urinary bladder cancer, prostate adenoma etc.), which may result in these symptoms.

The risk of overactive bladder syndrome is higher late in life. Critical age is 60 years – the elderly persons of this age have highest OAB frequency. Increase in the risk of OAB for men can also be explained by benign hyperplasia of prostate, which affects about half of all men at the age of 60. Thus, absence of hyperplasia not necessarily means age-related changes of urinary bladder, which are nearly identical in men and women.

It is assumed that postmenopausal period is also related to increased risk of OAB development. More than 60% of menopausal women have urination disorders. However a role of sex hormones is not quite clear. The results of replacement hormonal therapy in such patients are not so clear, and instead of improvement it may result in worsening of OAB symptoms. Thus many anatomic and physiological age-related changes can result in OAB symptoms development. Nevertheless urina incontinence cannot be considered as the only sign of ageing. In addition some functional disorders such as limited mobility and functional disorders of upper extremities, together with poor eyesight can worsen the course of OAB. It should be remembered that pharmacological preparations, used for treatment of concomitant diseases, can also play a part in it. For example diuretic agents may result in considerable increase in urination frequency and imitate OAB symptoms.

Treatment of urinary bladder dysfunction depends of etiology of pathological condition. Chronic cystitis requires antibacterial therapy; detrusor dysfunction requires atropine group medicines; neurogenic urinary bladder disorder – M-cholinoblockers (oxybutin, tolterodin, dariphnacin).

Clinical characteristic of the patients

Clinical study of Chitomur use was carried out at the Medical center of the Saint Petersburg Institute of Bioregulation and Gerontology during the period from March till November 2011. 28 men at the age from 45 to 62 years with a diagnosis benign prostate hyperplasia (BPH) and 31 women at the age from 48 to 56 years with a diagnosis overactive bladder (OAB) have taken part in the study. All the patients were complaining of urination dysfunction.

Distribution of the patients by clinical entities and age

Table 1

The patients of the main groups (18 men and 22 women) have been taking Chitomur in addition to the general purpose medicines – 1 capsule, 2 times a day before meal for 30 days. The patients of the control group (10 men and 9 women) received only general purpose treatment. Distribution of the patients by groups is shown in the table 1.

Chitomur efficiency was assessed on the basis of the patients complaints, general clinical examination of blood and urine, biochemical blood analysis, abdominal pressure level at urination and urine flow, fluorometric index.

Examination results

The results of clinical study of Chitomur have shown, that pollakiuria (polyuria) has completely disappeared in 88.3% of patients with BPH, 93.2% of patients does not need to urinate at night. Strangury (difficult urination) has disappeared in 74.8% patients and 26.7% of patients have noticed considerable improvement of the urine flow and alleviation of urination. Dynamics of the results in patients with BPH before and after the treatment course of treatment using Chitomur is shown in the table 2.

Influence of Chitomur on the urodynamics in patients with benign hyperplasia of prostate.

Table 2

The state of health of the patients with BPH after treatment using Chitomur was characterized by improvement of subjective and objective indices or urodynamics.

It is worth noting that uroflowmetry results, registered after treatment of patients with BPH of I and II stage, have shown restoration of basic urination parameters to normal values. In case of III stage of the diseases it was prevented by decrease in elasticity of bladder neck due to sclerotic changes of the prostate tissue, but the patient had considerable improvement of the urine flow.

Women with climacteric syndrome and concomitant overactive bladder after Chitomur course have notices 38% decrease in imperative micturate urges and 43% decrease in the episodes of urgent incontinence, besides the assessment by the patients of the condition of the bladder has also improved. The degree of discomfort has decreased 1,8 times due to elimination of imperative urges, anxiety degree has decreased by 57%, and treatment satisfaction has reached 78%. Thus according to self-assessment of the patients, the decrease in anxiety due to urination disorder symptoms 1,8 times is better than positive dynamics of the symptoms, that is a sign of prevailing improvement in the quality of life of the women after treatment.

In a month after the end of treatment using Chitomur, all the patients have achieved an improvement in symptoms. After the end of administration of the drug the capacity of the bladder in these patients has increased by 10-20% for different urges. That can be explained by decrease in detrusor ischemic, which is really important for OAB pathogenesis.

Thus the results of the study carried out confirm therapeutic efficiency of Chitomur and expediency of its application as a part of complex treatment of diuretic disorders of various origin, including diseases of prostate in men and women with overactive bladder symptoms.
Chitomur does not cause any side effects, complications and drug dependence and can be used for treatment and prophylaxis, including in combination with any means of symptomatic therapy, used for urological practice (antibacterialm spasmolytics, vascular and hormonal preparations, vitamins etc.)

Conclusion

The dietary supplement Chitomur regulates functional activity of the cells of the wall and detrusor of the bladder, and normalizes urination function. Chitomur is well tolerated by patients at oral administration; it does not result in any side effects and can be widely used as a treatment and prophylactic dietary supplement.

Chitomur is recommended to patients with urination disorders of various origins – per os at meal time 1-2 capsules 2-3 times a day for 30 days. It is recommended to carry out another treatment course in 3-6 month.

You can purchase original Khavinson peptide bioregulators from the official US distributor below.

References

  1. Mashkovsky M.D. Medicines: Pharmacotherapy for doctors, manual: 2 parts. – Vilnius: ZAO “Gamta”, 1993.
  2. Andrology manual / Edited by O.L. Tiktinsky L.: Medicine, 1990. – 416 pages
  3. Sexopathology: guide / Edited by G.S. Vasilchenko.- M.: Medicine, 1990. – 576 page

Clinical Study of Khavinson A-9 Pielotax Peptide

The dietary supplement Pielotax contains a complex of low-molecular peptides with molecular weight up to 5000 Da, isolated from kidneys of young animals – calves aged up to 12 months. Pielotax is manufactured in the form of capsules with a content of active substance of 10 mg.
Experimental studies have shown that the peptides possess tissue-specific action on the cells of the tissues from which they were isolated. Pielotax peptides regulate metabolism processes in the kidney tissue cells, increase urination system safety margins, having a favorable effect on the organism adaptation processes in extreme conditions, they possess anti-oxidative properties, regulating peroxide oxidation processes in the kidneys. So it is possible to extrapolate an efficiency of administration of Pielotax for restoration of the function of the kidneys and their disorders of various origins.

Metabolic disorders, essential hypertension, infectious and autoimmune disorders, especially age-related, frequently results in kidney affection (3).

Drug treatment of kidney diseases includes administration of the following drugs (1, 2):
· 4-aminoquinolinic series drugs (chloroquine, plaquenil)
· Iimmunomodulatory drugs (thymalinum, levamisole)
· Hypotensive drugs
· Vitamins C and E (antioxidants); etc.

Clinical study of Pielotax was carried out at the Medical center of the Saint Petersburg Institute of Bioregulation and Gerontology since February till August 2011.

Clinical study of Pielotax was carried out in patients with gouty nephropathy; distribution of the patients by sex and age is shown in the table 1. In total 42 patients have been taking part in the study. The patients with gouty nephropathy were complaining of periodic pain in the joints. In connection with long term morbidity in some patients the inflammatory changes were subclinical. All the patients have been taking symptomatic and pathogenic therapy for the disease, which resulted in temporary reduction in intensity of the symptoms.

Using randomization method the patients were divided into 2 groups – control (15 people) and main (27 people). The patients of the control group have been taking general purpose medicines only. The patients of the main group have been taking Pielotax, in addition to the general purpose medicines – per os 10-15 minutes before meal 1-2 capsules, 3 times a day before meal for 30 days depending on intensity of the pathological process.

Distribution of the patients by diagnosis, sex and age

Table 1

Examination methods

The patient complaints were assessed and compared, general clinical studies of blood and urine were carried out together with blood biochemical test using “REFLOTRON” device (Boehringer Mannheim, Germany). Ultrasonic examination was carried out using ultrasonic device (ALOKA, Japan).

Examination results

As a result of the studies performed it was established that administration of Pielotax lead to decrease in clinical signs of nephropathy in case of gout in 78% of cases. However, most significant were the results of laboratory tests. The drug administration resulted in activation of metabolism of kidney tissues and intensification of secretory kidney function, which is reflected in dynamics of biochemical indices of the patients (table 2).

According to the data shown in the table 2, the patients of the control group, treated using general purpose methods, had an improvement of biochemical blood indices, reflecting the kidney function. However these indices did not reach normal values. In patients of the basic group the biochemical parameters has reached normal values for men and women. Thus, non-protein nitrogen in the control group has made on the average before treatment 35,4±0,8 (mmol/l, and after treatment – 30,5±0,6 (mmol/l (p<0,05), however in patients of the basic group the parameter decreased to 27,1±0,4 (mmol/l, which is definitely lower in comparison to the control group and corresponds to lower normal limit (28,6 (mmol/l). Same tendency can be seen in the dynamics of the blood urea: decrease in the initially elevated parameter in patients of both groups, however in the basic group this parameter has made 9,2±0,3 (mmol/l, which is close to its normal value (8,3 (mmol/l). There are also characteristic changes of uric acid content: both in men and women of the basic group after additional use of the drug under examination, the parameters were normalized – in men the amount of uric acid has decreased to 0,44±0,02 (mmol/l (in the control group 0,56±0,01 (mmol/l, norm up to 0,50 (mmol/l); in female of the basic group – up to 0,37±0,03 (mmol/l (in the control group 0,48±0,02 (mmol/l, norm up to 0,40 (mmol/l).

Influence of Pielotax on biochemical blood parameters in patients with gouty nephropathy

Table 2

Thus the results obtain confirm treatment efficiency of Pielotax and expediency of its administration in complex treatment of patients with gouty nephropathy and other diseases related to kidney dysfunction.
Pielotax does not result in side effects, complications and drug dependence.

Pielotax can be used as medical and preventive mean in the form of dietary supplement and in the form of adjunct in combination with any means of symptomatic and pathogenic therapy, used for treatment of patients with gouty nephropathy and other kidney diseases.

Conclusion

The dietary supplement Pielotax normalizes metabolism in kidney tissues. Pielotax is well tolerated by patients at oral administration; it does not result in any side effects and can be widely used as a treatment and prophylactic dietary supplement.
Pielotax is recommended to patients with gouty nephropathy and other diseases per os 10-15 minutes before meal 1-2 capsules 2-3 times a day for 15-30 days depending on severity of the pathological process. It is recommended to carry out repeated treatment courses in 3-6 month.

You can purchase original Khavinson peptide bioregulators from the official US distributor below.

References

  1. Belousov Y.B., Moiseev V.S., Lepakhin V.K. Clinical pharmacology and pharmacotherapy: Manual for doctors. – M.: Universum, 1993. – 398 pages
  2. Mashkovsky M.D. Medicines: Pharmacotherapy for doctors, manual: 2 parts. – Vilnius: ZAO “Gamta”, 1993.
  3. Geriatry manual / Edited by D.F. Chebotarev, N.B. Mankovsky. – M.: Medicine, 1982. – 544 pages

Clinical Study Of Khavinson A-8 Endoluten Peptide

The dietary supplement Endoluten contains a complex of low-molecular peptides with molecular weight up to 5000 Da, isolated from pineal gland (epiphysis) of young animals – calves aged up to 12 months. Endoluten is manufactured in the form of capsules with a content of active substance of 10 mg.

Experimental studies have shown that the peptides possess tissue-specific action on the cells of the tissues from which they were isolated. Endoluten peptides regulate metabolism processes in neuroendocrine cells of various tissues, including epiphysis, increase neuroendocrine system safety margins, having a favorable effect on the organism adaptation processes in extreme conditions; they possess anti-oxidative properties, regulating peroxide oxidation processes in various tissues. So it is possible to extrapolate an efficiency of administration of Endoluten for restoration of neuroendocrine regulation in case of its disorders of various origins. According to the results of experiments, Endoluten provides normalization of neuroendocrine regulation of basic functions of the organism.

It is well known, that decrease in functional activity of epiphysis results in decoupling of nervous, endocrine and immune systems, and provide development of various diseases and pathological conditions. An influence of extreme environmental, climatic-geographic, professional, psycho-emotional factors on human organism also results in neuroendocrine and immunological disorders, causing disadaptation disorders and psychosomatic diseases (3, 4, 5, 6).

Medicinal treatment of the diseases and pathological conditions includes application of various medicines, depending on symptoms of the disease. However the correction of the disorders is based on prescription of various medicines (1, 2):

• Adaptogens (ginseng, eleuterococcus, Rhaponticum carthamoides, Snowdon rose extracts, spikenard, devil’s-club infusions, saparal, pantocrin);
• Peptide immunomodulators (timalin, tactivin, timogen, mylopeptide);
• Epiphysis hormone (melatonin)
• Epiphysis peptides (epitalamin)
• Multivitamins etc.

However the drugs have side effects and cannot be prescribed for prevention of the listed pathological conditions. In this connection development of new effective and safe means for prophylaxis and increase in efficiency of treatment of patients with pathological conditions, related to neuroendocrine regulation disorders, is an pressing issue.

Clinical studies of Endoluten were carried out in 163 patients (including 48 men and 115 women) with dyshormonal myocardiodystrophy, physiogenic asthenia, mild and moderate climacteric syndrome in women and in oncological patients after the courses of radiation and chemotherapy, who have undergone a course of treatment at the Medical center of Saint Petersburg Institute of Bioregulation and Gerontology of the Northwest Branch of the Russian Academy of Medical Sciences from January 2011 to August 2011. Distribution of the patients by clinical entities, sex and age is shown in the table 1.

Distribution of the patients by clinical entities, sex and age

Table 1

The patients were randomized into 2 groups, according to their clinical entity: control groups included 64 persons taking general purpose treatment for their diseases (1, 2). The patients with hormone replacement therapy were not included in the study.

The patients of the main group have been taking Endoluten in addition to the general purpose medicines – 1-2 capsules, 2-3 times a day before meal for 15-30 days depending on intensity of the pathological process.

Examination Methods

Endoluten efficiency study was carried out on the basis of generally accepted examination methods. The patient complaints were assessed and compared; general clinical studies of blood and urine, biochemical blood test, electrocardiogram were carried out. The number and functional activity of peripheral blood lymphocytes were assessed using immunological methods. The hormone content (follicle-stimulating hormone and luteinizing hormone) in blood serum was determined using radioimmunological method. An assessment of psychophysiological parameters was made using correction task and Lüscher test.

Examination Results

Endoluten administration in patients with dyshormonal myocardiodystrophy has resulted in improvement of subjective parameters of the disease, which resulted in decrease in the number of heart pain attacks, increase in working capacity and normalization of psychoemotional condition.

Endoluten influence on the amount of hypothesis hormones in blood serum оf patients with dyshormonal myocardiodystrophy

Table 2

Endoluten administration resulted in positive ECG dynamics. Determination of the level of hormones in the blood serum in patient of the basic group has helped to identify a decrease in the level of initial elevated FSH from 89,3±3,5 mU/ml to 46,8±3,9 mU/ml, while normal range is 1,5-45 mU/ml, and in patients of the control group only to 71,6±6,3 mU/ml, which is reliably lower than the parameter before treatment, however much higher than norm (table 2). The same tendency was observed in the LH content dynamics: in patients of the main group under Endoluten influence this parameter has decreased to normal values, while in the control group it has considerably decreased in comparison with the parameter before treatment, but was much higher than norm. Estradiol content, which was initially reliably decreased in female patients of both groups, has increased from 65,4±5,2 pmol/l to 101,3±7,2 pmol/l and was closer to the normal value (110-734 pmol/l), while in patients of the control group this parameter has elevated only to 79,1±4,2 pmol/l.

The study carried out has helped to identify corrective influence of Endoluten on hormonal disbalance, which resulted in normalization of metabolism in myocardium tissues, which has correlated with improvement of the clinical picture of the disease.

Same tendencies of normalization of the hormonal status were observed in patients with climacteric syndrome of mild and moderate degree: Endoluten results in restoration of the hypophysis hormone balance, which correlated with relief of main symptoms. The results of study of Endoluten efficiency in women with climacteric syndrome are shown in table 3.

According to the table 3, administration of Endoluten in patients with climacteric syndrome resulted in improvement of subjective parameters, which caused a reliable decrease in the number of pain attacks in comparison with the parameters before treatment, in the area of heart, dizziness, heart “freezing” feeling and sleep improvement. Besides it resulted in decrease in the number of complaints of tachycardia attacks, perspiration, hot flashes in the head and upper body, blood pressure fluctuation in comparison with patients before treatment and after treatment using general purpose medicines (table 3). After the course of Endoluten the patient have noticed considerable increase in working efficiency, which they related to normalization of psychoemotional condition. What stands out in the report is the fact, that the preparation effect was characterized by stable aftereffect. So in 1-2 month after the end of the course of Endoluten, the symptoms like dizziness, tinnitus, general weakness, sleep disturbances did not relapse.

Dynamics of subjective parameters in patients with climacteric syndrome

Table 3

Endoluten was also used for complex therapy of men with physiogenic asthenia. The preparation effected marked corrective action on the dynamics of subjective parameters. Men with physiogenic asthenia were complaining of general weakness, dizziness, high fatigability, decreased working capacity and sleep disturbances.

An addition of Endoluten to the treatment schedule of this category of patients resulted in elimination of objective symptoms, which resulted in fast and effective improvement of the general condition, while in patients of the control group, taking only general purpose therapy, the condition improvement was very slow and after the end of treatment subjective neurological symptoms have returned. It is significant that Endoluten treatment has marked aftereffect: after the end of application of the drug the improvement of the patient condition remained and was stable during the whole period of observation – no more than 1-3 month.

Thus Endoluten administration is a perspective direction for the therapy of pathological conditions connected to neurovegative function disorders, including climacteric syndrome, physiogenic asthenia, vegetative-vascular dystonia and other psychovegative disorders.

Oncological patients have been also taking Endoluten, they were the patients mainly with hormone-dependent tumors (breast cancer, cervical cancer and other locations), after surgical treatment and after courses of radiation and chemotherapy as a adjunct to the general purpose treatment. The patients were complaining of un-wellness, decreased muscular tone, decrease in appetite, apathy. Before treatment all the patients had changes of hemogram, mostly leucopenia and lymphocytopenia.

Influence of Endoluten on immunological parameters of blood of oncological patients

Table 4

Endoluten administration in oncological patients of the basic group resulted in reliable increase in the total number of leucocytes, lymphocytes and T-lymphocytes of the blood, and improvement of functional activity of T-cells (table 4). The indicated changes were correlated with positive dynamics of subjective condition: appetite and sleep improvement, increase in the muscle tone, decrease in apathy.

The study results have shown that Endoluten is expedient in oncological patients after the courses of radiation and chemotherapy for improvement of the general condition, keeping an optimum level of hematological and immunological indices in peripheral blood, preventing a development of infectious complications.

Inclusion of Endoluten into the complex treatment of various diseases, related to neuroendocrine regulation disorders, does not result in any side effects, drug dependence, contraindications.

Thus the results obtained confirm treatment and prophylactic efficiency of Endoluten and expediency of its administration in complex treatment and prophylaxis of patients with various pathological conditions and diseases related to neuroendocrine regulation of the main functions of the organism.

CONCLUSION

The dietary supplement Endoluten normalizes metabolism in neuroendocrine system cells, in particular the pineal gland (epiphysis) and promotes restoration of neuroendocrine regulation and basic functions of the organism.

Endoluten is well tolerated by patients at oral administration; it does not result in any side effects and can be widely used as a treatment and prophylactic dietary supplement.

Recommended Endoluten dosage

· In patients with dyshormonal myocardiodystrophy – per os 10-15 minutes before meal 1-2 capsules 2-3 times a day for 15-30 days depending on severity of the pathological process.
· In patients with mild and moderate climacteric syndrome per os 10-15 minutes before meal 1-2 capsules 2-3 times a day for 30-60 days depending on severity of the pathological process.
· In patients with physiogenic asthenia – per os 10-15 minutes before meal 1-2 capsules 2-3 times a day for 15-30 days depending on severity of the pathological process.
· In oncological patients after radiation or chemotherapy – per os 10-15 minutes before meal 1-2 capsules 2-3 times a day for 30 days depending on severity of the pathological process.
· For prophylaxis in patients, whose professional activity is connected to psychoemotional stress, high physical and emotional loads – per os 10-15 minutes before meal 1 capsule, 2 times a day for 15-30 days.
Carry out another treatment course in 3-6 months if needed. It is expedient to recommend Endoluten for treatment and prophylaxis use.

You can purchase original Khavinson peptide bioregulators from the official US distributor below.

References

  1. Karpov R.S., SlepoushkinV.D., Mordovin V.F., Havinson V.H., Morozov V.G., Grischenko V.I. Use of epyphisis drugs in clinical practice. – Tomsk: Publishing house of Tomsk university, 1985. – 152 pages
  2. Mashkovsky M.D. Medicines: Pharmacotherapy for doctors, manual: 2 parts. – Vilnius: ZAO “Gamta”, 1993.
  3. Novikov V.S., Smirnov V.S. Immune physiology of extreme conditions. – SPb.: Nauka, 1995. – 172 pages
  4. Pierpaoli V., Regelson U. Magic of melatonin: Translated from English. – M.: Vostochnaya knizhnaya compania, 1997. – 256 pages
  5. Slepoushkin V.D., Anisimov V.N., Havinson V.H., Morozov V.G., Vasiliev N.V., Kosykh V.A. Epiphysis, immunity and cancer. – Tomsk: Publishing house of Tomsk University, 1900. – 148 pages
  6. Teppermen G., Teppermen H. Physiology of metabolism and endocrine system: Translated from English. – M.: Mir, 1989. – 656 pages

Clinical Study of Khavinson A-7 Svetinorm Peptide

The dietary supplement Svetinorm is a complex of low-molecular peptides with molecular weight up to 5 000 Da, isolated from liver of young animals – calves aged up to 12 months. Isolated peptides possess tissue-specific action to liver cells, thus restoring metabolism and normalizing their functional activity.

Svetinorm is manufactured in the form of capsules, containing 10 mg of active peptides. The clinical studies of Svetinorm were carried out at the Medical Center of the Saint Petersburg Institute of Bioregulation and Gerontology of the Northwest Branch of the Russian Academy of Medical Sciences in patients with chronic hepatitis and oncological patients after the course of radiation and chemotherapy during the period from October 2005 till January 2006.
Svetinorm was administered per os 10-15 minutes before meal 1-2 capsules 2 times a day for 10-20 days depending on severity of the pathological process.
Now we see an increase in the number of patients with chronic liver diseases, which affect mostly able-bodies persons. They are mainly caused by unfavorable social and environmental factors. Chronic hepatitis is not an outcome of acute infectious process, but the form of clinical course of infectious process (2, 3).
Now the treatment of patients with chronic hepatitis in view of pathogenic mechanisms is carried out using the following traditional therapeutic agents (1):
· drugs, which improve metabolism of hepatic cells (hepatoprotectors, essentiale, legalon, sirepar)
· bile secretion stimulators (Liv-52)
· B group vitamins (B1, B6, B12), ascorbic acid etc.

Clinical characteristic of the patients

The clinical studies were carried out in 47 patient with chronic hepatitis and oncological patients after the course of chemotherapy, including 30 men and 17 women in the age from 35 to 68 years (table 1). The disease period has made from 3 to 10 years old. The patients of the main group have also been taking Svetinorm in addition to the general purpose medicines – 2 capsules, 2 times a day before meal for 15-20 days.
The control groups consisted of 38 similar patients, which have only general purpose treatment.

Distribution of the patients by clinical entities, sex and age

Table 1

Most patients were complaining of the pain in the right hypochondrium, general weakness and rapid fatigability, 73% of patients had dyspepsia. 53% of patients had bilirubinemia, increase in the level of alanine aminotransferase, increase in the globulin fraction of the blood proteins, mainly due to M immunoglobulin fraction, which is a sign of specific activity of chronic inflammation process.

Examination methods

The complaints were assessed subjectively at different times. The following tests were carried out: general clinical test of blood and urine, biochemical and immunological blood test (determination of immunoglobulins using Mancini method), liver ultrasound.

Examination results

After treatment using Svetinorm, most patients noticed elimination of fatigability, improvement of appetite and working capacity. 53% of patients have noticed considerable decrease in intensity of pain syndrome.
Oncological patients have noticed condition improvement, decrease in fatigability, decrease in intensity of dyspeptic disorders.

Influence of Svetinorm on Biochemical parameters of peripheral blood in patients with chronic hepatitis

Table 2

At the analysis of Svetinorm efficiency special attention should be paid to the assessment of the results of biochemical examinations, characterizing aminotransferase activity, pigment and protein-synthesis function of liver. Objectively, most patients after Svetinorm treatment have noticed stabilization of biochemical indices: bilirubin level, alanine aminotransferase level (table 2). Analysis of immunoglobulins of peripheral blood, being significant criterion of activity of inflammatory process after the course of treatment using Svetinorm, has resulted in a decrease in IgM level (table 3).

Thus the obtained results testify hepatoprotective properties of Svetinorm and expediency of its use for complex treatment of acute and chronic liver disorders, in oncological patients after radiation and chemotherapy, and also for prophylaxis of various liver diseases and their complications.
During clinical studies of Svetinorm there were no side effects, contraindications, complications and drug dependence.

Influence of Svetinorm on immunological parameters of patients with chronic hepatitis

Table 3

Recommendations for use

Svetinorm is recommended for acceleration of restoration of liver function at acute and chronic affection, at treatment with antibiotics and other medicines with unfavorable liver effect, at hypoalimentation, in oncological patients after radiation and chemotherapy, at influence on the organism of various factors. It is also indicated to elderly people for maintenance of the liver function.
It is recommended to take Svetinorm per os 10-15 minutes before meal 1-2 capsules, 2-3 times a day for 15-20 days. It may be desired to have one more course in 3-6 months.

You can purchase original Khavinson peptide bioregulators from the official US distributor below.

References

  1. Mashkovsky M.D. Medicines: Pharmacotherapy for doctors, manual: 2 parts. – Vilnius: ZAO “Gamta”, 1993.
  2. Podymova S.D. Liver diseases. – M.: Medicine, 1984. – 480 pages
  3. Rakhmanova A.G., Prigozhina V.K., Neverov V.A. Infectious diseases: Manual for general practitioners. – M.-SPb.: Pub. “SSZ”, 1995. – 304 pages

Clinical Study of Khavinson A-6 Vladonix peptide

The dietary supplement Vladonix contains a complex of low-molecular peptides with molecular weight up to 5000 Da, isolated from thymus of young animals – calves aged up to 12 months. Vladonix is manufactured in the form of capsules with a content of active substances 10 mg.

Experimental studies have shown that the peptides possess tissue-specific action on the cells of the tissues from which they were isolated. Vladonix peptides regulate metabolism processes in the immune system cells, they restore the immunological reactivity that has been infringed; stimulate regeneration processes in case of their inhibition. Thus it is possible to extrapolate efficiency of Vladonix for restoration of immune system function at different purulent-inflammatory and other diseases, characterized by suppression of the immune status of the patients.

It is well known, that various factors of physical, chemical and biological nature depending on duration and intensity of their influence on human organism, can result in deterioration of adaptation and compensatory mechanisms and may cause profound disorders of various segments of the immune protection system (2, 3). Pathological changes of the immune system, as a rule, results in long-term course of basic disease with a tendency to relapses, reduction in resistance of the organism to infections and severe complications.

Among the drugs, promoting recovery of immunological reactivity, are immunomodulator drugs of various origin: enzyme preparations (tripsin, lysocim), bacterial polysaccharides (pyrogenal, prodigiosan), yeast polysaccharides (zymosan, glucanes, prepermil, dextranes), vaccines (BCG), nucleic acid preparations (sodium nucleinate), purine and pyrimidine derivatives, levamisol, diucifon, traditional medicine preparations and many others (1, 2).

The clinical studies of Vladonix were carried out at the Medical Center of the Saint Petersburg Institute of Bioregulation and Gerontology in patients after long-term low-dose ionizing radiation influence, including oncological patients after radiation and chemotherapy during the period from November 2005 till February 2006.
The subjects of the clinical studies were 42 patients (23 men and 19 women) – apart from general purpose medicines they were taking Vladonix per os before meal 1-3 capsules 2-3 times a day for 15-20 days depending on a degree of immune status disturbances. The patients of the control group have been taking general purpose medicines only. The age of patients has made from 34 up to 65 years. Distribution of the patients by clinical entities, sex and age is shown in the table 1.

Distribution of the patients by clinical entities, sex and age

Table 1

Examination

Vladonix efficiency was assessed by changes of the patients’ complaints and by the number of objective parameters: general clinical analysis of blood and urine, immunological study of peripheral blood (number of T- and B-lymphocytes was determined by immunofluorescence method with monoclonal antibodies to differentiation lymphocyte antigens CD3, CD4, CD8, CD20; content of various classes immunoglobulins – using a method of radial immune diffusion in a gel using Mancini method; functional activity of T-lymphocytes – using leukocyte migration inhibition test (LMIT) with ConA).

The tests performed have shown, that 92 % of persons, living in the environmentally neglected territory, have immune status disorders in the form of decrease in the number of CD3+, CD4+cells, at insufficient increase in the number of lymphocytes with CD8+phenotype, which is a sign of decrease of the immune reactivity level (CD4+/CD8+). The results of LMIT with ConA characterize a decrease in functional activity of T-lymphocytes (mostly CD8+, i.e. T-suppressors/killers). The number of CD20+-cells, being a subpopulation of B-lymphocytes, was not different from normal values, but at the same time there was an increase in the number of M and G immunoglobulins in blood serum (table 2).

It is important to note that quantitative indicators of content of CD3+ and CD4+ cells are typical for lower limits of physiological changes of their number in the patients of such age that is a possible sign of premature ageing of the immune system. As a rule people with secondary immune-deficiency condition has intense asthenic syndrome and considerable changes of cardiovascular system.

Vladonix influence of the cellular and humoral immunity parameters in patients, who have undergone low-dose ionizing radiation influence

Table 2

The results of the test performed provide strong evidence of the fact, that Vladonix is an effective mean for correction of secondary immune deficiency, being a response to influence of extreme factors. Administration of Vladonix together with symptomatic means has helped to normalize infringed parameters of immune system in 78 % of cases. According to the data provided, the highest effect observed of Vladonix administration was identified in subpopulations of T-lymphocytes and in their functional activity (reliable increase in the number of CD3+- and CD4+-lymphocytes, normalization of CD4+/CD8+ratio). Less intense reaction was notices in B-system, probably, due to its higher conservativity.

After the treatment course using Vladonix, the patients, which have noticed considerable improvement of general condition and decrease in intensity of asthenic syndrome, always parallel to secondary immune deficiency. Oncological patients after radiation and chemotherapy had increased normalization of immunological indices, which resulted in improvement of general condition and decrease in the rate of complications. What stands out in the report is the fact, that patients of the basic group tolerated radiation and chemotherapy better and was able to finish the whole course of treatment (control group – 79 %).

Conclusion

Clinical studies have shown, that Vladonix promotes normalization of cellular immunity parameters, stimulated tissue regeneration processes in case of their inhibition, does not result in any side effects, complications and drug dependence, and can be used for treatment and prophylaxis in parallel with any means of symptomatic and pathogenetic therapy, used for correction of secondary immune deficiency conditions (immune modulators, adaptogens, vitamins etc.). Vladonix is recommended for acceleration of restoration of the immune system functions after the infectious diseases, radiation and chemotherapy, influence on the organism of various extreme factors (including ionizing and UHF-radiation). It’s also recommended to elderly people for maintenance of the immune system function.

It is recommended to take Vladonix per os 10-15 minutes before meal 1-3 capsules, 2-3 times a day for 20-30 days. It may be desired to have one more course in 3-6 months. The clinical study showed no side effects, complications, contraindications and drug dependence of Vladonix.

You can purchase original Khavinson peptide bioregulators from the official US distributor below.

References

  1. Drannik G.N., Grinevich Y.A., Disik G.M. Immunotropic preparations. – Kiev Zdorov’ya, 1994. – 288 pages.
  2. Mashkovsky M.D. Medicines: Pharmacotherapy for doctors, manual: 2 parts. – Vilnius: ZAO “Gamta”, 1993.
  3. Novikov V.S., Smirnov V.S. Immune physiology of extreme conditions. – SPb.: Nauka, 1995. – 172 pages.
  4. Schek M.G., Kosinets A.N., Adamenko G.P. Immunological aspects of surgical infection. – Vitebsk: B. i., 1994. – 140 pages

Clinical Study of Khavinson A-5 Cerluten Peptide

The dietary supplement Cerluten contains a complex of low-molecular peptides with molecular weight up to 5 000 Da, isolated from the brain tissues of young animals – calves aged up to 12 months. Cerluten is manufactured in the form of capsules with a content of active substances of 10 mg.

Experimental studies have shown that the peptides possess tissue-specific action on the cells of the tissues from which they were isolated. Cerluten peptides regulate metabolism processes in the brain cells, increase brain safety margins, having a favorable effect on the organism adaptation processes in extreme conditions, the possess anti-oxidative properties, regulating peroxide oxidation processes in the brain cortex. So it is possible to extrapolate an efficiency of administration of Cerluten for restoration of the function of the central nervous system and its disorders of various origins.

Treatment of central nervous system diseases is of specific urgency, because they lead to social adaptation disorder and invalidation of patients (2). Now the treatment of patients with disease of central nervous system diseases in view of pathogenetic mechanisms is carried out using the following traditional therapeutic agents of various action types(1, 3):

Influence on metabolism and integrative functions of the brain (cerebrolysin, piracetam, encephalolysate).
Normalization of cerebral and systemic circulation (stugeron, vinpocetine).
Reduction of psychopathological signs (meridin, amitriptilin).
Correction of changes of bioelectric activity of the brain (phenobarbital, convulex).
Influence on liquorodynamic disorders (veroshpiron, furosemide).
Prevention and inhibition of adhesive process (aloe, lidasa).
Correction of immunopathological reactions (levamisole, tavegil).
The clinical studies of Cerluten were carried out at the Medical Center of the Saint Petersburg Institute of Bioregulation and Gerontology of the Northwest Branch of the Russian Academy of Medical Sciences in 48 patients with various diseases of central nervous system: long-term effects of craniocerebral injury (the prescription of the injuries was from 1 year to 10 years), state after stroke, vascular encephalopathias, decrease in mental capacity, memory, attention during the period from October 2003 till February 2004. Distribution of the patients by clinical entities, sex and age is shown in the table 1. The patients of the main group have been taking Cerluten in addition to the general purpose medicines – 1-2 capsules, 2-3 times a day before meal for 10-20 days depending on intensity of the pathological process.

The control group consisted of 37 similar patients, which have only general purpose treatment. All the patients have been taking symptomatic and pathogenetic drugs, these drugs have resulted in short-term therapeutic effect, which required increase in a dose of the drugs per treatment course and duration of their administration.

Distribution of the patients by clinical entities, sex and age

Table 1

Examination methods

Cerluten efficiency was assessed by dynamics of subjective parameters and objectively, using correction task and electroencephalography (EEG) methods.

Examination results

After administration of Cerluten in patients of the main group the clinical result was observed in 64.6% of cases, satisfactory – in 22.9%, absence of positive effect – in 12.5% of cases (control group – table 2). There were no negative influences of Cerluten on a condition of the patients.

Cerluten efficiency in patients with diseases of central nervous system

Table 2

At comparison of subjective parameters of the condition of the patients before and after use of Cerluten it was established that the number of health complaints was 2-3 times less. The patients have noticed memory impairment, intelligence impairment, decrease in intensity and duration of headache, emotional disbalance, endurance and stamina, feeling of rest after night sleep (table 3). In patients with consequences of craniocerebral injury and stroke there was a moderate regression of focal symptoms, improvement of speech function at motor and sensor aphasia, decrease in muscular spasticity. Comparative assessment of influence of Cerluten and other methods of treatment on the integral function of the brain – attention and bioelectric activity of the brain was assesses using correction task and electroencephalography accordingly.

Influence of Cerluten on subjective parameters of the state of health of the patients.

Table 3

Influence of Cerluten on the dynamics of parameters of carrying out of correction task by the patients with diseases of central nervous system

Table 4

The results of carrying out by the patients of the correction task after treatment using various methods are shown in table 4. According to the table, the patients after treatment using Cerluten have higher number of symbols viewed and lower number of errors. The patients of the main group have received better results at analysis of the dynamics of carrying out of correction task before and after the treatment in comparison with the patients of the control group. It was expressed by absence of violent oscillations of the number of the symbols viewed per similar time periods, presence of “warming-up” period to the middle of the task performance and gradual decline of the curve to the end of the task, which is a sign of highest attention stability after treatment.
Assessment of Cerluten influence on bioelectric activity of the brain was carried out using visual analysis of EEG with distribution by types and calculation of alpha index before and after the treatment. EEG was carried out selectively to the patients with more expressed signs of pathological processes. The examination results are shown in the table 5.

Cerluten influence on electorencephalogram type characteristic in patients with diseases of central nervous system

Table 5

Before treatment the people examined in various groups predominantly had pathological EEG types (III, IV, V). III type of EEG was characterized by so called non-dominant curve at low amplitude level (below 30-35 mcV), presence of irregular alpha-activity or even its absence. IV type of EEG was characterized by particularly emphasized regularity of the rhythms, blurring of zonal differences. V type of EEG was characterized by presence of irregular slow activity with an amplitude over 35 mcV, sharp waves, paroxysmal discharges.
Patients after treatment using Cerluten had most intense changes of brain bioelectric activity. Is was seen on EEG first of all in the form of more clear modulation and restoration of zonal differences of alpha-rhythm, decrease in intensity of irritative processes, in some cases – elimination of paroxysmal discharges.

Cerluten influence on the dynamic of alpha index changes in patients with diseases of central nervous system

Table 6

Besides visual EEG assessment there was a calculation of alpha index in patients before and after treatment (table 6). It was established that under the influence of the treatment there was a reliable increase in the alpha index in the patients of the groups examined. However the decree of change of alpha index in patients, receiving different treatment was different. Alpha-index value was reliably higher in the group of patients after treatment using Cerluten® in comparison with the parameters in other groups.

Conclusion

On the basis of the data received it is justifiably to draw a conclusion that activation of reserve capacity of the brain cortex using Cerluten helps to improve integral functions of the brain. Thus the results of clinical study testify the efficiency and expediency of use of Cerluten for complex treatment and prophylaxis of the diseases of the central nervous system of various origins. Cerluten does not result in side effects, complications and drug dependence; there were no contraindications for carrying out of clinical studies. Cerluten can be used for treatment and prophylaxis, including in combination with any means of symptomatic therapy, used for neurological practice (vascular, nootropic, resolving, anticonvulsants, vitamins etc.)

Recommendations for use

Cerluten is recommended for acceleration of restoration of the brain functions after the craniocerebral injury, stroke, intellectual disorders and the influence on the organism of various extreme factors. It’s also indicated to elderly people for maintenance of the mental capacity. It is recommended to take Cerluten per os 10-15 minutes before meals 1-2 capsules 2-3 times a day for 10-30 days. It may be desired to have one more course in 3-6 months. There are no contraindications and side effects for Cerluten administration.

You can purchase original Khavinson peptide bioregulators from the official US distributor below.

References

  1. Kovalev G.V. Nootropic medicines. – Volgograd: Nizh.-Volzh. publishing house, 1990. – 368 pages
  2. Treatment of nervous diseases: Translated from English/ Edited by V.K.Viderholt. – M.: Medicine, 1984. – 560 pages
  3. Mashkovsky M.D. Medicines: Pharmacotherapy for doctors, manual: 2 parts. – Vilnius: ZAO “Gamta”, 1993.X

Clinical Study Of Khavinson A-3 Ventfort Peptide

The dietary supplement Ventfort contains a complex of low-molecular peptides with molecular weight up to 5000 Da, isolated from the vascular (aorta) tissue of young animals – calves aged up to 12 months. Ventfort is manufactures in the form of tablets or capsules with a content of active substances 10 mg.

Experimental studies have shown that the peptides possess tissue-specific action on the cells of the tissues from which they were isolated. They improve trophism of the vascular wall cells and provide regulating action on the metabolic processes in them, provide normalization of functional and morphological changes in the vascular wall, they regulate blood content of cholesterol and lipoproteins, thus decreasing a risk of various vascular defects. So it is possible to extrapolate an efficiency of use of Ventfort for recovery of vascular function at various diseases, including vascular atherosclerosis.

Atherosclerosis and its consequences is one of the main causes of invalidation and death in developed countries. Age related changes of vascular wall and hemodynamic disorders results in decrease of peripheral blood flow, vascularization of bodies and tissues, development of various components of oxygen insufficiency and trophesies. (2, 3, 4, 6).

Drug treatment of atherosclerosis is aimed at normalization of lipid metabolism, blood coagulation processes and metabolism in the vascular walls (1, 5).

Medicines, which normalize cholesterol and b-lipoproteins level.
Those drugs which prevent cholesterol absorption in intestines, (cholestiramin, b-sitosterol, diosponine, polysponine).
Drugs which affect cholesterol synthesis in an organism, (clofibrate, miscleron, regardin, cetamifen, nicotinic acid, vitamin PP);
Those drugs which increase disintegration and excretion of cholesterol from an organism (linetol, arachiden).

Others that improve microcirculation and normalize vascular permeability, decrease edema of vascular tissues and improving metabolic processes in the vascular walls (prodectine, dicynon, doxium, glivenol, escusane etc.)

The clinical studies of Ventfort were carried out at the Medical Center of the Saint Petersburg Institute of Bioregulation and Gerontology in patients with atherosclerosis of various arteries and senile purpura during the period from November 2005 till February 2006.

Clinical characteristic of the patients

The subjects of the clinical studies were 49 patients with arterial atherosclerosis and senile purpura, 27 of them were the main group (15 men and 12 women) – they were additionally prescribed Ventfort per os 10-15 minutes before meal 1-2 capsules 2-3 times a day for 10-15 days depending on a degree of pathological process. 22 patients (11 men and 11 women) in the control group have been taking only general purpose medicines. The age of both groups of patients has made from 52 up to 84 years old.

The patients of both groups have various clinical signs depending on affection of various caliber vessels: essential hypertension, ischemic heart disease, cerebrovascular disorders with memory impairment, clouded sensorium and affective liability. All the patients had progressive dynamics of pathogenic pathway. All the patients have been taking symptomatic and pathogenic therapy for specific clinical signs of vascular pathology.

Distribution of the patients by clinical entities, sex and age

Table 1

Examination methods

The patient complaints were assessed and compared, general clinical studies of blood and urine were carried out together with blood biochemical test using “REFLOTRON” device (Boehringer Mannheim, Germany). Blood coagulogram and tourniquet Hesse testing were carried out with a purpose of homeostasis assessment.

Examination results

It was established that Ventfort administration in patients with arterial atherosclerosis has resulted in improvement of general state of health, especially in patients with cerebrovascular disorders.
As you can see in the table 2, Ventfort administration has resulted in reliable decrease in the level of general blood cholesterol. There were also a tendency towards decrease in the content of very little density lipoproteins, being most atherogenic.
The patients with senile purpura after Ventfort administration had an increase in strength of capillary walls according to the results of Hesse testing, the frequency of hemorrhages has decreased. In most patients the skin and hair condition has improved.

Influence of Ventfort on the lipid metabolism values in patients with arterial atherosclerosis

Table 2

Ventfort administration in patients with senile purpura has resulted in improvement of skin condition and in increase in strength of capillaries, confirmed by Hesse test results. The frequency of hemorrhage marks has decreased.

Thus the results of the study performed testify therapeutic efficiency of Ventfort and expediency of its application as a part of complex treatment of atherosclerosis and vascular pathology. Ventfort administration has not resulted in any side effects, complications, contraindications and drug dependence. Ventfort is convenient for administration in hospital, out-patient conditions and at home.
Ventfort can be used as medical and preventive mean in the form of biologicall active food additive in the form of adjunct for complex therapy of vascular atherosclerosis and improvement of microcirculation in different tissues in combination with any means of symptomatic and pathogenetic therapy.

Conclusion

The biologically active peptide bioregulator Ventfort provides regulation of blood cholesterol and lipoproteins contents and promotes improvement of vascular wall condition. Ventfort is well tolerated at oral administration, does not have any side effects, does not have any contraindication and can be used as an adjunct to complex treatment and prophylaxis of vascular disorders of various geneses.

Ventfort is recommended for improvement of the function of vascular wall in case of atherosclerosis, microcirculation disorders in the bodies and tissues art various diseases, influence on the organism of various extreme factors. It is also recommended to elderly people for maintenance of the vascular system function.

Recommended dosage

Per os 10-15 minutes before meal 1-3 capsules, 2-3 times a day for 10-20 days. It is expedient to carry out the treatment courses every 3-6 months.

You can purchase original Khavinson peptide bioregulators from the official US distributor below.

References

  • Belousov Y.B., Moiseev V.S., Lepakhin V.K. Clinical pharmacology and pharmacotherapy: Manual for doctors. – M.: Universum, 1993. – 398 pages.
  • Blood diseases in elederly people: Translated from English/ Edited by M. G. Danham, I. Chanarina. – M.: Medicine, 1989. – 352 pages.
  • Hormones and vascular diseases: Translated from English/ Edited by R.M. Grrenhalg M.: Medicine, 1984. – 344 pages.
  • Korkushko O.V. Cardiovascular system and age. – M.: Medicine, 1983. – 176 pages.
  • Mashkovsky M.D. Medicines: Pharmacotherapy for doctors, manual: 2 parts. – Vilnius: ZAO “Gamta”, 1993.
  • Geriatry manual / Edited by D.F. Chebotarev, N.B. Mankovsky. – M.: Medicine, 1982. – 544 pages.

Clinical Study of Khavinson A-1 Suprefort peptide

The dietary supplement Suprefort is a complex of low-molecular peptides with molecular weight up to 5000 Da, isolated from pancreas of young animals – calves aged up to 12 months. Isolated peptides possess tissue-specific action to pancreas cell tissue, thus restoring metabolism and normalizing its functional activity.

Suprefort is manufactured in the form of capsules, containing 10 mg of active peptides. Suprefort was administered per os 10-15 minutes before meal 1-2 capsules 2 times a day for 10-20 days depending on severity of the pathological process.

The clinical studies of Suprefort were carried out at the Medical Center of the Saint Petersburg Institute of Bioregulation and Gerontology in patients with Chronic pancreatitis in the state of remission and in patients with Diabetes mellitus II during the period from November 2005 till January 2006.

Deregulation of physiological functions and pathological changes in pancreas result in diseases with signs of nutrition and metabolism disorders. Consequences of progressive inflammatory process in pancreas are, as a rule, dystrophic processes accompanied with disorders of excretion of digestive pancreatic enzymes, characteristic for chronic pancreatitis. In the presence of disorders of insulin secretion, the patient has symptoms of ‘secondary’ diabetes mellitus.

Diabetes mellitus is one of most widespread endocrine diseases: about 1-2% of Earth’s population has it. Besides there are same amount of people with occult diabetes and genetically predisposed to this disease. The diabetes signs in any single case are integrated reaction to mutual action of multiple factors with various combinations (genetic predisposition, chemical and infectious agents of environment, autoimmune processes, nutrition, physical activity, psychological stresses etc.). Detection of new syndromes (diabetes, caused by formation of antibodies to insulin receptors; diabetes caused by genetic defects of insulin structure etc.) is a reason of constant necessity of addition of disease classification. Potential, latent and asymptomatic forms of the diseases without clinical symptoms require special attention concerning prognosis, prophylaxis and treatment (1, 3, 6, 7, 8). Treatment of chronic pancreatitis is based mainly on diet and enzyme preparations (pancreatin, pansinorm) etc. (5) Treatment of diabetes mellitus without clinical signs requires diet therapy and phytotherapy (2, 4).

Clinical characteristic of the patients

Distribution of the patients by diagnoses, sex and age is shown in the table 1. Treatment using Suprefort was carried out in 34 patients (18 male and 16 female) with diagnoses ‘Chronic pancreatitis, latent form’ (12 persons) and ‘Diabetes mellitus II type, latent form’ (22 persons). The patients with chronic pancreatitis were complaining of the loss of appetite, eructation, meteorism, borborygmus, stool disorders. Two groups of patients were formed using random sampling technique, in these groups the patients have similar sex, age and diagnosis: the basic group included 12 patients (8 men, 4 women), control group – 8 patients (4 men, 4 women).

Distribution of the patients by diagnosis, sex and age

Table 1

The patients of the control group have been taking general purpose medicines. The patients of the main group have been taking Suprefort in addition to the general purpose medicines – 1-2 capsules, 2 times a day before meal for 15 days.
Diabetes mellitus II in the patients was not accompanied by any clinical signs and was diagnosed on the basis of an increase in glucose level in peripheral blood in view of unbalanced diet.
Control group included 17 patients, who have been taking general purpose medicines. 22 patients of the main group have also been taking Suprefort in addition to the general purpose medicines – 1 capsule, 2 times a day before meal for 15 days.

Examination methods

The patient complaints were assessed and compared, general clinical studies of blood and urine were carried out together with blood biochemical test using ‘REFLOTRON’ device, (Boehringer Mannheim, Germany). Duodenal content was examined. Glucose tolerance test was carries out.

Examination results

It was established that administration of Suprefort in patients with chronic pancreatitis resulted in increase in appetite and decrease in the rate of dyspepsia.

Suprefort influence of activity of digestive enzymes in patients with chronic pancreatitis

Table 2

Laboratory assessment of duodenal content has shown initial decrease in activity of pancreatic enzymes (table 2). After Suprefort administration there is tendency toward increase in activity of pancreatic enzymes, which correlated with improved clinical symptoms.

Suprefort in patients with diabetes mellitus II was administered in parallel with glucose tolerance test. It was established that after glucose challenge the patients had characteristic glycemic curve. The patients of the main group have also been taking Suprefort in addition to the general purpose medicines – 1 capsule, 2 times a day before meal for 10 days. It was shown, that after Suprefort administration the test carried out in 2 hours after beginning of the study showed gradual decrease in the glucose level. In 5-10 days after beginning of the treatment course the patients had normal glucose levels. None of the patients had increased dosage of blood glucose lowering drugs, 12 patients (54,5%) were using decreased levels of general purpose medicines and in 7 patients (31,8%) the blood glucose level was below normal values without blood glucose lowering drugs. In 3 patients (13,6%) the parameters remained at the initial level. It is worth noting the stabilization of the blood glucose parameter in the patients of the main group within next 2-3 month after the end of treatment (table 3).

Suprefort influence on blood glucose values after glucose loading in patients with diabetes mellitus II

Table 3

In patients of the control group, who have been taking general purpose blood glucose lowering drugs, it was not possible to lower the dosage of the medicines, and in 9 patients (52,9%) the dosage of blood glucose lowering drugs was increased with a purpose of normalization of content of blood glucose.
Thus the results of the clinical study obtained confirm an efficiency of Suprefort and expediency of its use in complex treatment of the patients with chronic pancreatitis and diabetes mellitus II.

Suprefort does not result in side effects, complications and drug dependence. Suprefort is convenient for administration in hospital, out-patient conditions and at home. Suprefort can be used as medical and preventive mean in the form of biological active food additive and in the form of adjunct in combination with any means of symptomatic and pathogenetic therapy, used for treatment of patients with chronic pancreatitis and other diabetes mellitus II.

Conclusion

The dietary supplement Suprefort normalizes functional activity of pancreas cells.
Suprefort is well tolerated by patients at oral administration; it does not result in any side effects and can be widely used as a treatment and prophylactic biologically active food additive for complex treatment of pancreatic function disorders.

Recommended Suprefort dosage

In patients with chronic pancreatitis – per os 10-15 minutes before meal 1-2 capsules, 2 times a day for 15 days.
In patients with diabetes mellitus – per os 10-15 minutes before meal 1 capsule, 2 times a day for 15 days in parallel with blood glucose monitoring.
It is expedient to carry out another treatment course in 3-6 month if needed.

You can purchase original Khavinson peptide bioregulators from the official US distributor below.

References

  1. Balabolkin M.I. Diabetes mellitus / Endocrine disorders // Diagnostics and treatment of internal diseases: Manual for doctors. – Edited by F.I.Komarova. – M.: Medicine, 1991. – V. 2. – pages 465-492.
  2. Belousov Y.B., Moiseev V.S., Lepakhin V.K. Clinical pharmacology and pharmacotherapy: Manual for doctors. – M.: Universum, 1993. – 398 pages
  3. Internal diseases / Edited by A.S. Smetnev, V.G. Kukes. – M.: Medicine, 1982. – 496 pages
  4. Yordanov D., Nikolov P., Boychinov Asp. Phytotherapy. – Sofia: Medicine and physical culture, 1972. – 346 pages
  5. Mashkovsky M.D. Medicines: Pharmacotherapy for doctors, manual: 2 parts. – Vilnius: ZAO “Gamta”, 1993.
  6. Geriatry manual / Edited by D.F. Chebotarev, N.B. Mankovsky. – M.: Medicine, 1982. – 544 pages
  7. Teppermen G., Teppermen H. Physiology of metabolism and endocrine system: Translated from English. – M.: Mir, 1989. – 656 pages
  8. Ugolev A.M., Radbil O.S. Digestive system hormones. – M.: Nauka, 1995. – 283 pagesDiabetes mellitusDiabetes mellitusDiabetes mellitusDiabetes mellitusDiabetes_mellitusDiabetes_mellitus